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ABSTRACT

Bedi, Shimpi Ph.D., Biomedical Sciences Ph.D. program, Department of Biochemistry
and Molecular Biology, Wright State University, 2017. Identification of novel ligands
and structural requirements for heterodimerization of the liver X receptor alpha.
LXRs, LXRα (NR1H3) and LXRβ (NR1H2), are ligand-activated transcription
factors that are members of the nuclear receptor superfamily. Oxysterols and nonsteroidal
synthetic compounds bind directly to LXRs and influence the expression of LXR
dependent genes. The use of murine models and LXR-selective agonists have established
the important role of LXRs as sterol sensors that govern the absorption, transport, and
catabolism of cholesterol. Upon activation, these receptors have been shown to increase
reverse cholesterol transport from the macrophage back to the liver to aid in the removal
of excess cholesterol. Not surprisingly, LXR dysregulation is a feature of several human
diseases, including metabolic syndrome. Due to their roles in the regulation of lipid and
cholesterol metabolism, LXRs are potentially attractive pharmaceutical targets. As ligand
binding and dimerization play pivotal roles in modulating LXR activity, the identification
of novel ligands and requirements for LXR dimerization can potentially aid the drug
development process. Herein, using a variety of biophysical assays, including
fluorescence based assays coupled with in silico molecular modeling, I have identified
medium chain fatty acids and/or their metabolites as the novel endogenous agonists of
LXRα. There is mounting evidence that ligand induced dimerization regulates the
transcriptional output of nuclear receptors. Thus, it is important to identify factors that
iv

modulate protein-protein interactions. This work demonstrated that (a) LXRα binds
PPARα with a high affinity (low nanomolar concentration), (b) ligands for LXRα alter
the binding dissociation constant values of LXRα-PPARα interaction, and (c) ligand
binding induces conformational changes in the dimer secondary structure. Furthermore,
site-directed mutagenesis investigated the strength of individual contributions of residues
located in the ligand binding domain to dimerization and transactivation properties of
LXRα. Data herein highlight the importance of hydrophobic interactions and salt bridges
at the interface, and suggest that key interface residues are required for the liganddependent activation of LXRα in a promoter specific manner. Mutagenesis of LXRα
L414 to an arginine revealed the importance of this site in dimerization, specifically with
RXRα. This work showed that this particular mutation specifically abolished
dimerization with RXRα. Taken together, this study provided insights into the functional
roles of fatty acids as novel LXRα ligands and the effects mutations may have in
modulating molecular interactions and activity profile of LXRα.
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INTRODUCTION

METABOLIC SYNDROME
Nuclear receptors (NRs), described as metabolic nuclear receptors by Francis et al.,
2003 are activated by dietary nutrients or metabolite intermediates which act as metabolic
and toxicological sensors (Fig.1). These receptors allow the organism to adapt and
survive in an ever-changing environment by inducing the appropriate metabolic genes
and pathways. It has been demonstrated that nuclear receptors play central roles in; (a)
energy and glucose metabolism through peroxisome proliferator-activated receptor
gamma (PPAR γ); (b) fatty acid, triglyceride, and lipoprotein metabolism via PPAR α, δ,
and γ; (c) reverse cholesterol transport and cholesterol absorption through the liver X
receptors (LXRs); (d) bile acid metabolism through the farnesoid X receptor (FXR) and
LXRs; and (e) the defense against xeno and endobiotics by the pregnane X
receptor/steroid and xenobiotic receptor (PXR) (1, 2). An intricate signaling network
allows these receptors to maintain normal homeostasis of glucose, cholesterol,
triglycerides, and bile acids. Any disturbances in the equilibrium of this network is
associated with elevated circulating levels of free fatty acids, bile acids, oxysterols,
leading to dysregulation of the transcriptional activities of the nuclear receptors (3).
Much attention has been given to the role of NRs in the pathophysiology of metabolic
diseases including metabolic syndrome.
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Fig.1. Dietary lipids are endogenous ligands for nuclear receptors. Ligands for the
nuclear receptors, LXR, PPAR, and FXR are derived from the diet and from the
biosynthetic pathways that generate cholesterol and fatty acids from acetyl coenzyme A.
These lipophilic ligands diffuse through the nuclear membrane, bind to and stimulate the
transcriptional activities of the receptors. Image modified from (2).
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Metabolic syndrome is a clinical condition that is characterized by multiple
cardiovascular risk factors including obesity, hypertension, dyslipidemia, and abnormal
glucose metabolism. It is strongly associated with higher cardiovascular and total
mortality (4, 5, 6). Given that the activities of NRs are modulated via direct DNA
binding and by small endogenous lipophilic molecules as well as exogenous synthetic
molecules, they represent attractive therapeutic targets for the treatment of metabolic
syndrome (7, 8, 9).
The NR superfamily consists of 48 members in humans and 49 in mice. While they
are conserved from human to C. elegans, they are not present in plants and yeast,
suggesting their essential function in animal cells. NRs are composed of several domains
that mediate DNA-binding, dimerization, ligand binding, and transcriptional activities.
Synergistic and high-affinity dimeric DNA binding of nuclear receptors requires two
independent dimerization functions, one located within the DNA-binding domain (DBD)
and the second located in the ligand-binding domain (LBD) (10) (Fig. 2). NRs are
classified based on phylogeny, structure, and their ligand binding properties (11). The
segregation into these classes are indicative of their unique DNA binding properties,
ligands, and dimerization status on target genes.

4

Fig.2. Schematic of the domain organization of LXRα that typifies nuclear receptors. A
central DNA-binding domain or C domain is flanked by an N-terminal A/B domain and a
C-terminal ligand binding domain (LBD). The LBD harbors a ligand-dependent
transcriptional activity, a strong dimerization interface, and a ligand binding pocket.
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LIVER X RECEPTOR (LXR)
Liver X receptors belong to a large family of nuclear hormone receptors that play
important roles in cholesterol and lipid metabolism (12, 13). P. Willy and D. J.
Mangelsdorf, 1995 cloned LXRα by low stringency screening of a rat liver cDNA library
and named it based on its liver-rich expression pattern. In vitro transcription/translation
showed full-length hLXRα to contain 447 amino acids (M, 49,000) (14). LXRs were
initially classified as orphan receptors but were deorphanized with the identification of
oxysterols as their physiological ligands. Several other ligands, both natural and
synthetic, have since been classified as LXR ligands. There are two LXR isoforms in
mammals, termed LXRα (NR1H3) and LXRβ (NR1H2). Both isoforms are highly related
and share 78% identity of their amino acid sequences in both DNA and ligand-binding
domains. The expression pattern of the two LXR isoforms varies; whereas LXRα is
expressed in metabolically active tissues such as liver, spleen, intestine, kidney, lung, and
adipose tissues, LXRβ is ubiquitously expressed in all tissues examined (15).
LXRs form obligate heterodimers with the retinoid X receptor (RXR) and regulate the
expression of genes involved in bile acid and cholesterol metabolism through binding to
LXR response elements (LXREs) in the promoter regions of the target genes (10) (Fig.
3). These targets include ATP-binding cassette transporters A1, G5, and G8 (ABCA1,
ABCG5, ABCG8), apolipoprotein E (Apo E), and cholesterol ester transport protein
(CETP).

6

Fig.3. LXR and RXR form an obligate heterodimer that recognizes and binds to a direct
repeat of DR4 response element in the regulatory regions of their target genes. In the
absence of ligand, co-repressors are bound to the heterodimer and inhibit the transcription
of target genes. Upon ligand binding to either LXR or RXR, co-activator proteins are
recruited that initiate transcriptional activity.
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Additional targets of LXR are fatty acid synthase (FAS) and SREBP-1c that are key
lipogenic enzymes (16, 17). LXRE consists of two hexanucleotide sequences (AGGTCA)
separated by four bases (DR-4 element) (18) (Fig. 3). The LXR/RXR heterodimer is
activated by ligand binding to either partner and is, therefore, termed as a permissive
heterodimer. The mode of activation is similar to that observed with other members of
the hormone receptors. In the absence of ligand, the NRs repress transcription via direct
interactions with transcriptional co-repressor proteins such as N-CoR (NR co-repressor)
and SMRT (silencing mediator of retinoid- and thyroid-responsive transcription), and
subsequent recruitment of the histone deacetylase complex to target genes. Upon ligand
binding, there is a conformational change within the ligand binding domain (LBD) of the
NR that results in the exchange of co-repressor complex with the recruitment of
coactivators. The coactivator bound state converts the receptor from an inactive to an
active state and exhibits enhanced levels of gene transcription (19).

STRUCTURE OF LXR
LXR contain two well-defined structural domains: a DNA-binding domain (DBD)
and a ligand binding domain (LBD). The N-terminal region of LXR is highly variable
and has a ligand independent transactivation function. The DBD and LBD are linked via
a hinge region that displays very low amino acid identity and similarity between
receptors. The function of the hinge region is poorly understood, however, it can
influence transcription due to phosphorylation (11). The most conserved region within
the nuclear receptors is the DBD that is composed of two zinc finger motifs. The first
zinc finger contains the proximal- or P-box region, a short motif, responsible for
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recognizing the promoter and allowing the receptor to bind differentially to target genes
(20). The tertiary structure of the DBD contains alpha helices that bind to specific DNA
sequences called hormone response elements. The DBD is not only involved in response
element binding, but also serves as an allosteric transmitter of signals to other regions of
the receptor molecule (21). Located within the second zinc finger is the distal- or D-box
that provides a dimerization interface for nuclear receptor dimerization. Nuclear receptors
bind to DNA as heterodimers, homodimers, or monomers, depending on the class of NRs
(22).
Most nuclear receptors contain residues N-terminal to the DBD that mediate ligandindependent transactivation function (AF-1 function). The AF-1 sequence is not very well
conserved across the nuclear receptor superfamily. This region can activate transcription
in a constitutive manner. There is evidence that the AF1 activation function displays cells
and promoter specificity (23). Allosteric interactions between subunits allow the receptor
to function as efficient regulatory switches. The overall structure of the receptor may be
altered in a subtle or dramatic manner as a result of allosteric interactions (24).
The LBD exhibits at least 78% amino acid sequence identity between the two LXR
isoforms and constitutes the principal dimerization interface of this protein family. The
multifunctional LBD mediates dimerization, ligand binding, and ligand-dependent
transcriptional activity (25). X-ray crystallography established the apo and holo LXRα
LBD as organized as a three-layered α-helical sandwich structure (Fig. 4). The helices
have been designated H1 to H12 that are arranged in an antiparallel helix sandwich. Since
the three dimensional crystal structure is derived from the LBD of LXRα, regions of high
flexibility are not visible. Located at the core of the LBD is a hydrophobic ligand-binding

9

pocket (LBP) that accommodates the hydrophobic ligands (26). Several LXR LBD
structures complexed with ligands have been determined (26-29). Regardless of the type
of bound ligand, the LBD maintains the same overall arrangement of the alpha helices.
Ligand binding causes a major conformational change in the LBD. The structural
transition upon ligand binding has been described as a ‘mouse trap’ mechanism. In the
absence of ligand, H12 is located away from the LBD body. Ligand binding results in the
positioning of H12 to a new position on the surface of LBD that entraps the ligand (active
conformation) (30) (Fig. 5). This forms a hydrophobic binding groove for the binding of
coactivator such as steroid receptor coactivator (SRC) family of proteins. The
coregulators bind the receptors using LXXLL motifs located within their polypeptides
and bind helix 12 via a charge clamp. The recruiting of transcriptional coregulators
triggers activation or suppression of target genes (31). Antagonist may inhibit coactivator
binding by sterically blocking the positioning of helix 12 over the LBD core structure or
by promoting corepressor recruitment (26). Thus, nuclear receptors are molecular
switches that may be turned off or on depending on the positioning of H12 of the LBD
relative to the rest of the LBD.
Visual inspection of the LXRα LBD reveals that the LBP is shaped as a straight
cylinder and extends between helix 12 and the beta sheet located at the entrance of the
pocket. The volume of the LXRα LBP is in the range 700-800 A3. The ligands are
positioned centrally and the ligand-LBP interactions involve residues from helices 3, 5
and 7. Hydrophobic interactions and hydrogen bonds between the ligand and key residues
in the LBP determine the strength and specificity of LBD-ligand complex. The
hydrophilic region of the LBP, located near helices 1 and 5 and the β-sheet region found
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between helices 5, possesses several polar and charged amino acids. Key residues His
421 and Trp 443 (helices 11 and 12) located in the LXRα LBP stabilize the active
conformation of LXRα through direct interactions with the ligand (26).
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Fig.4. Crystal structure of LXRβ-RXRα complex on the DR-4 element in the presence of
respective agonists: GW3965 (LXRβ) and 9-cis Retinoid acid (RXRα). Image adapted
from the RCSB PDB entry 4NQA. Sections of the protein are not visible owing to
residual mobility in the crystal structure.
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Fig.5. Agonist binding in the LBD induces a conformational change in C-terminal helix
12 (AF2). In the active state, AF-2 forms a lid over the hydrophobic ligand binding
pocket to facilitate coactivator recruitment. In the absence of ligand, corepressor binds
the LBD to prevent gene transcription. Image adapted from reference (30).
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To date more than a dozen high resolution structures of LXR with various ligands and
in complexes with RXR have been deposited in the Protein Data Bank (PDB) (26, 32).
Using these crystal structures, it has been possible to identify putative residues that may
be involved with binding, the nature of the protein-protein interface, and the
conformational changes undergone by the proteins upon binding other macromolecules.
Considerable attention has recently been devoted to the regulation of the novel
heterodimeric pair composed of LXRα and PPARα. Because the LXRα-PPARα LBDs
have not been crystallized in a complex, the exact nature of protein-protein interactions is
unclear. However, the LBDs of each of these proteins have individually been crystallized
and might prove useful for predicting important interactions leading to LXRα-PPARα
heterodimerization. Molecular docking has proved to be a valuable tool for the
determination of the complex structure between two proteins by utilizing the structures
from the individually crystallized subunits as input. Among the popular protein docking
tools available to carry out such studies are AutoDOCK, HADDOCK, HEX, and
ZDOCK.

Ligands of LXR
Endogenous Agonists
Oxidized cholesterol derivatives (oxysterols) are endogenous ligands for LXR.
Among the oxysterols, 22(R)-hydroxycholesterol and 20(S)-hydroxycholesterol, 24(S)hydroxycholesterol, and 24(S), 25-epoxycholesterol bind LXR with the strongest
affinities at concentrations consistent with those found in tissues (Kd values ranging from
0.1-0.4 µM). Intermediates of cholesterol biosynthesis also activate LXRs through direct
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high affinity binding. 24(S), 25-epoxycholesterol is produced in a shunt of the
mevalonate pathway and activates LXR (15). Other intermediates such as desmosterol
and zymosterol also activate LXR (33). Fatty acids are known to modulate activation of
LXRα. Whereas trans-9, trans-11- conjugated linoleic acid transcriptionally regulates
LXR target genes (ABCA1 and ABCG1) in human macrophages, polyunsaturated fatty
acids antagonize ligand-dependent activation of LXRα by oxysterols (34-36).
Endogenous Antagonists
Highly unsaturated fatty acid, such as arachidonic acid, interfere with the activation
of SREBP-1c by functioning as a competitive antagonist of the activating LXRα ligand.
Arachidonate blocks activation of a synthetic LXR-dependent promoter in transfected
human embryonic kidney 293-cells (36). In addition, antagonists such as prostaglandin
F2α, small heterodimer partner interacting leucine zipper protein (SMILE), and
ursodeoxycholic acid have also been reported (37).
Exogenous Natural Ligands
Compounds derived from plants or fungi modulate LXR activity. These include
phytosterols and terpenes that bind LXRs (EC50 in the range of 33-136 nM as determined
in a coactivator peptide recruitment assay). Other reported natural agonists include
acanthoic acid, viperidone, polycarpol, and gorgostone derivative. Among the natural
compounds that act as LXR antagonists are guttiferone (IC50 value of 3.4 µM), riccardin
C, naringenin, genistein, taurine (2-aminoethanesulfonic acid), and dahuang (38).
Synthetic Ligands
Strong synthetic agonists such as T0901317 and GW3965 have been developed and
used as valuable tools in biomedical research (39, 40). Both agonists have EC50 values in
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the low nanomolar range for both isoforms of LXR. T0901317 is a non-steroidal
synthetic ligand composed of a tertiary sulfonamide and a bistrifluoromethyl carbinol
(EC50 value is 20 nM). Various studies have identified hydrogen binding between the
head group of T-0901317 and key residues in the LXR LBP to be critical for coactivator
recruitment and subsequent activation of LXR. GW3965 is another non-steroidal, tertiary
benzylamide that selectively activates LXRα (EC50 value is 648±178 nM). Both ligands
are associated with hypertriglyceridemic effects in mouse model, therefore, preventing
the use of these agonists in clinical trials in human subjects (41, 42). Multiple research
groups have modified existing ligands to develop novel ligands that are potent agonists,
exhibit anti-inflammatory activity without the concomitant hypertriglyceridemic effects.
Present research has continued to focus on developing potent ligands that might exhibit
enhanced specificity and selectivity for LXRβ over LXRα.

HETERODIMERIZATION OF LXR
LXRα, in addition to forming dimers with RXR, binds peroxisome proliferatoractivated receptor α (PPARα) (43, 44). Little research has followed to investigate the
quantitative values, namely the dissociation constant values (Kd), for the heterodimer
composed of full-length LXRα and PPARα proteins in the presence of LXRα ligands.
Our laboratory has previously reported the effect of endogenous PPARα ligands on
LXRα-PPARα interaction. We concluded that whereas palmitic acid, oleoyl CoA, and
linoleic acid enhance LXRα-PPARα interactions, oleic acid, palmitoyl CoA, and
eicosapentaenoic acid inhibit this interaction. LXRα-PPARα heterodimer has the ability
to bind both the LXR response element (LXRE) and PPAR response element (PPRE).
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However, the affinities with which LXRα-PPARα complex binds its response elements is
lower than their corresponding dimers formed with RXRα [44]. A new PPARα-LXRα
response element has recently been identified that regulates a semi-distinct set of genes or
pathways ((Klingler, A. M., 2016. Novel Insight into the Role of LXRα in Metabolic
Regulation via DNA Binding as a Heterodimer with PPARα and as a Homodimer
(Master’s thesis) Ohio Link Document number: wright1472486254)). Ligand binding to
either or both protein(s) could affect the secondary structure of the complex, co-factor
recruitment, and the ability to bind DNA for gene regulation. Examination of the effects
of ligand binding on the formation of heterodimeric complexes will provide insight into
the regulatory features of these systems.
The reported crystal structure of LXRα-RXRβ (1UHL) provides important
information about the residues that form the dimer core. The LXRα-RXRα, and
presumably LXRα-PPARα, interface is formed mainly by the interactions of residues that
are components of helices H9 and H10 of LXRα. Significant changes in accessible
surface area were observed in residues H383, E387, and H390 located in helix 9 upon
LXRα dimerization resulting in the formation of novel salt bridges (26). The relative
contribution of the individual amino acid residues to receptor dimerization is unknown.
The most common approach to determine which residues contribute to binding utilizes
site directed mutagenesis. The best candidates for LXRα mutagenesis should be the
amino acid residues which strongly interact with the partner receptor. Mutation of
putative contact points at the LXRα interface is expected to exhibit one or all of the
following defects: (1) failure to form heterodimers, (2) failure to form heterodimers with
PPARα, but not RXRα, or vice versa, (3) reduced heterodimerization along with
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enhanced LXRα homodimerization, and (4) altered affinity of the mutant LXRα for its
ligands, DNA, or coactivators due to allosteric effects.
Visual examination of the interface of the three-dimensional crystal structure of
LXRα LBD shows that residues H383, E387, H390, L414, and R415 could provide direct
sites of interaction at the protein-protein interface (26). Modifications of any one or a
combination of these residues may cause subtle repositioning of residues or provide
additional stabilization to the interface resulting in selective LXRα dimerization
properties. Alternatively, mutations at these sites may not be accommodated in the
heterodimer three-dimensional structure due to unfavorable electrostatic or steric
interactions both close and distant to the interface. This will result in the inability of the
LXRα to form dimers with either RXRα or PPARα. Because the LBD is associated with
ligand binding, mutations in the LBD may perturb ligand binding. For example, a
mutation in the LXRα LBD (R415A) exhibits a phenotype similar to that of a mutant
lacking the AF2 helix and is unable to transactivate an ADH-LXRE x2-luc reporter in
response to T-0901317 addition (45). Whether mutations at the interface may impact the
ligand binding properties of LXRα has yet to be tested.
Alignment of human sequence of the LXRα LBD to corresponding sequences of
other species and receptors such as farnesoid X receptor (FXR), VDR, PPAR, and
retinoid acid receptor (RAR) shows complete conservation of residues at positions
homologous to E379, L414, and R415 in LXRα (Fig. 6). The conservation strongly
suggests an important structural and/or functional role of these residues. In addition,
LXRα residues H383, E387, and H390 have charged residues at corresponding positions
in other nuclear receptors. To identify the residues that are essential for dimerization,
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surface area of LXRα that is accessible to the solvent was calculated using Swiss PDB
Viewer (SPDBV) software. Fig. 7 illustrates that the LXRα LBD has been colored
according to the solvent accessibility of the residues (least accessible or buried residues
are colored violet and most exposed residues are colored red). LXRα residues (H383,
E387, H390, and R415) within helices 9 and 10 are more exposed (green) compared to
residues in their vicinity (blue). The LXRα-RXRβ complex reveals that H383, E387, and
H390 of LXRα could stabilize intermolecular contacts by forming salt bridges with E465,
A469, and E472 of RXRβ (corresponding to E394, A398, and E401 of RXRα) (26).
However, the proof of the identity of PPARα residues that participate in protein-protein
interactions with LXRα awaits the crystal structure of the LXRα-PPARα complex.
Several studies have demonstrated that modification of amino acid residues at the
interface is sufficient to alter the dimerization properties of the nuclear receptors (22, 46,
47). For example, mutation of mouse RXRα alters its dimer specificity, such that mRXRα
Y402A is deficient in dimerization with the Retinoid A receptor (RAR), PPAR, and the
vitamin D receptor (VDR), but acquires an enhanced tendency to form homodimers (22).
Since LXRα can heterodimerize to either RXRα or PPARα, this suggests that
modification of LXRα interface may provide a mechanism to determine the heterodimer
choice.
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Fig.6. Alignment of helices 9 and 10 of the LBDs of hLXRα, hFXR, hVDR, hPPARα,
and hRXR (top). Amino acid residues predicted to be critical for dimerization based on
the crystal structure of LXRα LBD are colored in red. Alignment of helix 10 of LXRα
LBD (bottom) showing complete conservation of amino acid residues among species.
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Fig.7. Solvent accessibility of LXRα residues showing surface exposed residues.
Multiple potential protein-protein binding sites were identified by computational analysis
using the reported crystal structure of LXRα-RXRβ heterodimer. LXRα LBD was
extracted from PDB entry 1UHL using SPDBV. Helices are colored based on solvent
accessibility: green regions are more exposed compared to regions in blue.
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REGULATION OF LXR EXPRESSION AND ACTIVITY
LXR signaling is modulated by both ligand binding and changes in receptor
expression. Expression of LXRα in human macrophages, adipocytes, hepatocytes, skin
fibroblasts and myotubes is controlled by an autoregulatory mechanism suggesting that
LXRα can regulate its own expression. This activity is mediated through the presence of
a functional LXRE located in the promoter of the human, but does not occur in mouse,
LXRα (48). Interestingly, a functional peroxisome proliferator-response element (PPRE)
has been identified in the human and rodent LXR gene promoter; it suggests that PPAR
could regulate the LXR pathway (49). Indeed, agonists of PPAR α and γ stimulate LXRα
expression in human and rodent macrophages, adipocytes, and hepatocytes (50). Insulin
and bacterial lipopolysaccharide have also been demonstrated to modulate the expression
of

LXRα.

Additionally,

LXRs

can

be

posttranslationally

modified

through

phosphorylation (Protein kinase A and C), acetylation, and sumoylation. These
modifications have been shown to affect LXR’s stability, gene specificity, and
transactivation properties (51-54).

FUNCTION OF LXR
There is abundant evidence that indicates that LXR-RXR heterodimers control various
aspects of cholesterol transport, metabolism, and biosynthesis (15). LXRs act as
cholesterol sensors to prevent cells from accumulating toxic levels of cholesterol through
triggering various adaptive mechanisms. For example, oxidized form of low-density
lipoproteins (ox-LDL) are recognized and internalized by the scavenger receptor CD36 in
the macrophages. Intracellular catabolism of ox-LDL leads to the generation of
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endogenous LXR ligands (oxysterol) which upregulate ATP-binding cassette transporter
(ABCA1) (Fig. 8) (13). The removal of excess cholesterol from macrophage foam cells
by high density lipoprotein and its principal apolipoprotein, apoA-1 prevents cells from
oxysterol-induced toxicity. In general, activation of LXR results in: (a) stimulation of
reverse cholesterol transport- a pathway that removes excess cholesterol from peripheral
tissues to liver and conversion of cholesterol to bile for biliary excretion, (b) inhibition of
intestinal cholesterol absorption, and (c) inhibition of cholesterol synthesis and uptake by
the cells.

23

24

Fig.8. Model showing LXRα mediated cholesterol efflux to HDL via ABCA1 from
macrophages. Binding of oxidized-LDL (Ox-LDL) to cell surface receptors such as
CD36 leads to internalization and degradation generating ligands for the activation of
LXR/RXR heterodimer on target genes such as ABCA1. Upregulation of ABCA1 results
in enhanced efflux of cholesterol to apoA1 component of HDL. Image adapted from the
reference (13).
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LXR and Reverse cholesterol transport: Reverse cholesterol transport (RCT) is a
pathway by which excess cholesterol is transported from peripheral tissues to the liver
followed by biliary secretion and subsequent disposal via the feces. Free cholesterol can
leave the macrophage either through a transporter-independent mechanism or dependent
on cholesterol transporters, mainly the ABCA1 and ABCG1. Another key player in
cholesterol efflux and macrophage-specific RCT is apoE. Interestingly, LXR agonists
induce the transcription of ABCA1 and apoE that raise HDL-C levels and reduce
atherosclerosis in animal models (55-57). The ability of LXR to promote macrophage
reverse cholesterol transport makes it a potential therapeutic target in the prevention of
atherosclerotic vascular disease.
LXR and Cholesterol synthesis: LXRs, in addition to regulating cholesterol
metabolism, are involved in induction of fatty acid and triglyceride biosynthesis in
response to feeding. This mechanism ensures that excess acetyl-CoA, an intermediate
product of glucose metabolism, is converted into fats and triglycerides. Activation of
LXR stimulates fatty acid synthesis through upregulation of key enzymes implicated in
hepatic lipogenesis. The major isoform responsible for hepatic lipogenesis is LXRα. The
lipogenic effect is mediated by increased expression of sterol regulatory element-binding
protein-1c (SREBP-1c) (51). Yoshikawa et al, 2001 have identified two LXREs within
the SREBP-1c gene promoter, and demonstrated that agonists of LXR and RXR increase
its transcriptional activity (58). In addition to directly regulating SREBP-1c expression,
LXR regulates several other lipogenic enzymes including acetyl-CoA carboxylase
(ACC), fatty acid synthase (FAS), and stearoyl-CoA desaturase-1 (SCD-1) (59).
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LXR and cholesterol uptake: LXR helps maintain cholesterol homeostasis not only
through promotion of cholesterol efflux, but also through suppression of low-density
lipoprotein (LDL) uptake. The major part of cholesterol in human blood is transported
within LDL-C. The LDLR mediates the removal of LDL and remnant lipoproteins from
circulation by binding to apolipoprotein B-100 and ApoE. LXR agonists GW3965 and
T0901317 markedly inhibit the binding and uptake of LDL by cells. The mechanism for
feedback inhibition of cholesterol uptake is independent of and complementary to the
sterol regulatory element-binding protein pathway (60).
LXR and intestinal cholesterol absorption: LXR activation results in a reduced
absorption of intestinal cholesterol by regulating the expression of genes such as
ABCG5/ABCG8 and Niemann-Pick C1-like 1 involved in this process. The enhanced
expression of ABCG5/ABCG8 transports absorbed cholesterol back to the lumen of the
intestine. Therefore, it is unsurprising that administration of LXR agonists decreases
intestinal net cholesterol absorption in mice (60). This observation suggests that intestinespecific agonists of LXR might prove beneficial in promoting cholesterol efflux in
chronic disorders such as atherosclerosis, inflammation, and cancer.
LXR and fecal neutral sterol excretion via intestine: Consistent with its role in
controlling key steps in removal of excess cholesterol from the body, LXR activation
leads to increased fecal sterol loss in mice models. Administration of LXR agonist T0901317 to mice enhances removal of blood-derived free cholesterol through
transintestinal cholesterol excretion. This effect is independent of ABCA1-mediated
elevation of HDL and the presence of ABCA1 in liver and intestine (60). Thus, excretion
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of excess cholesterol via the intestine represents an alternative route for cholesterol
disposal.
Apolipoprotein-mediated cellular lipid efflux and ABCA1: The expression of ABCA1
is tightly regulated by the cellular content of cholesterol, through oxysterol-dependent
activation of LXR. An LXR response element has been identified in the human ABCA1
promoter that binds both isoforms of LXR and mediates transcriptional induction of the
promoter by LXR ligands. This suggests that the expression of ABCA1 and the process
of cellular cholesterol efflux are controlled, at least in part, by the LXR signaling
pathway. In vivo data has further underscored the potential usefulness of synthetic LXR
agonists in the prevention or treatment of atherosclerosis via induction of ABCA1 in
macrophages and fibroblasts (61).
HDL-cholesterol and ApoA1: Since cholesterol is a water-insoluble molecule, it must
be packaged and transported within the plasma in the form of lipid/protein (lipoprotein)
complexes. High-density lipoprotein (HDL) particles transport cholesterol from tissues
back to the liver for excretion. HDL exists in two forms, one containing apolipoprotein
A-1 (ApoA-I) and apolipoprotein A-II (Apo-II), and one containing ApoA-I alone. The
cardioprotective effect of HDL is largely due to ApoA-1 (13, 62). Experimental
manipulations to increase production of ApoA-1 has been associated with reduced
atherogenicity. ApoA-1 promoter contains a functional PPRE (63) that makes fibrates
and PPAR agonists interesting options for enhancing HDL levels. However, the
beneficial effects of LXR and/or PPAR activation are accompanied by enhanced hepatic
lipogenesis and high triglyceride levels. This observation has hampered the use of LXR
and PPAR agonists in the treatment of cardiovascular, metabolic, and/or inflammatory
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diseases. There is a need for novel strategies to increase endogenous ApoA-1 that would
be a major step in treating lipid-related cardiovascular disease (64). Whether
manipulation of LXRα-PPARα heterodimeric pair presents an alternative route for
enhancement of ApoA1 has not been investigated yet.

ANIMAL MODELS
Insights into LXR function in metabolism have been provided by the generation of
LXR mutant mice. These studies have allowed better definition of the role of LXRs in
lipid synthesis, clearance, and catabolism. LXRα, but not LXRβ, knockout mice
accumulate large amounts of cholesterol esters in the liver after being fed a high-fat
cholesterol diet due to failure of inducing expression of CYP7A1 gene (19). In contrast to
this observation in rodents, LXRα agonist treatment suppresses the expression of
CYP7A1 in primary human hepatocytes (60). These results highlight the mechanisms
different species employ to regulate cholesterol homeostasis. To date, the use of mouse
models of atherosclerosis have shown an ability of LXR to decrease atherosclerosis via
ABCA1 expression. Overexpression of the human ABCA1 transgene in normal mice led
to an increase in HDL and decrease in atherosclerosis suggesting that enhancement of
HDL may be a useful route to pursue in the development of anti-atherosclerotic therapies.
However, the development of LXR agonists for the treatment of metabolic syndrome has
been difficult due to undesirable properties in animal models (65). Nevertheless, majority
of the studies provide evidence that LXRs are key players in maintaining metabolic
homeostasis in health and disease by regulating inflammation and lipid/carbohydrate
metabolism.
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LDL and HDL: “Bad” and “Good” Cholesterol
Complex particles called lipoproteins carry cholesterol in the plasma. These molecules
have a central core containing cholesterol esters and triglycerides that is surrounded by
free cholesterol, phospholipids, and apolipoproteins. Two important types of lipoproteins
are low-density lipoprotein (LDL) and high-density lipoprotein (HDL). The role of
LDLs, particularly the role of oxidized LDL, in damaging arterial walls leading to the
development of atherosclerotic lesions is well documented. On the other hand,
epidemiological studies have demonstrated an inverse relationship between HDL
cholesterol levels and cardiovascular disease risk. Thus, lowering of cholesterol-rich LDL
lipoproteins or upregulation of HDL through apoA-I may be crucial in patients with
coronary artery disease and individuals prone to atherosclerosis (64).
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DEVELOPMENT OF HYPOTHESIS
First, there is evidence of fatty acids modulating LXR activity suggesting that
interaction of fatty acids with LXRα may play a role in LXRα function. These data
synthesized the hypothesis that there may be direct interaction between LXRα and fatty
acids (34-36). Second, activation of LXRα-RXRα and PPARα-RXRα complexes via
agonist treatment could induce lipid accumulation via stimulation of SREBP-1c and its
response genes encoding key lipogenic enzymes (39, 51). Despite continuous efforts of
the pharmaceutical industry to design compounds that can circumvent triglyceridemia
and steatosis associated with the activation of these complexes, no specific drug has
provided therapeutic benefits. Activation of LXRα-PPARα provides an alternate route of
LXRα activation by which these side effects may be minimized. In the absence of
quantitative information about the binding of full length LXRα to PPARα, the
dissociation constant values for binding had to be determined both in the absence and in
presence of ligands. Previous experiments have indicated that the dimerization interface
and the ligand-binding pocket of the NRs are energetically linked (45) suggesting that
ligand binding modulates the side-chain dynamics of key residues at the interface.
The objectives of this study are to elucidate (1) whether fatty acids constitute high
affinity ligands of LXRα, (2) quantitatively characterize the LXRα-PPARα interaction,
and (3) identify positions within the LBD of LXRα that are required for its
transactivation properties. The ability to generate engineered receptors that are capable of
selectively forming distinct dimeric complexes may prove useful in enhancing our
understanding of the distinct roles of each heterodimeric pair.
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I tested the overall hypothesis that ligand binding determines heterodimer choice
through rearrangement of critical residues in helices 9 and 10. The specific aims of
this thesis are: (Specific aim 1) An investigation of the effect of chain length and degree
of unsaturation on fatty acid binding to LXRα; (Specific aim 2) The effect of LXRα
ligands on the heterodimerization of wild-type LXRα with its novel partner receptor
PPARα was studied; and (Specific aim 3) The effects of mutating LXRα interface
residues H383, E387, H390, L414, and R415 on heterodimerization, ligand binding, and
transactivation properties of LXRα were determined. A previously reported LXRα
mutant R415A (lacks LXRα-RXRα transactivation activity in the context of ADH
promoter when treated with an LXRα agonist T-0901317) (45) and novel LXRα mutants
(H383E, E387Q, H390Q, and L414R) were used to investigate whether mutations of
LXRα selectively impact dimerization, ligand binding, and/or transactivation properties.
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CHAPTER I

FATTY ACID BINDING PROFILE OF THE LIVER X RECEPTOR ALPHA
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1.

Abstract
Liver X receptor (LXR) alpha is a nuclear receptor that responds to oxysterols and

cholesterol overload by stimulating cholesterol efflux, transport, conversion to bile
acids, and excretion. Synthetic (T-0901317, GW3695) and endogenous (oxysterols)
ligands bind to LXRα which then regulates LXRα action.

LXRα activity is also

modulated by fatty acids (FA) but the ligand binding specificity of FA and acyl-CoA
derivatives for LXRα remains unknown. I investigated whether LXRα binds FA or FA
acyl-CoA with affinities that mimic in vivo concentrations, examined the effect of FA
chain length and the degree of unsaturation on binding, and investigated if FA regulate
LXRα activation. Saturated medium chain FA (MCFA) exhibited binding affinities in
low nanomolar concentration range, while long-chain fatty acyl CoA did not bind or
bound weakly to LXRα. Circular dichroism and computational docking confirmed that
MCFA bound to the LXRα ligand binding pocket similar to the known agonist
(T0901317) but without inducing a major conformational change. Transactivation assays
showed MCFA activated LXRα, whereas LCFA caused no effect. These results suggest
that LXRα functions as a receptor for saturated FA or acyl-CoA of C10 and C12 in length.
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2.

Introduction
Nuclear hormone receptors are ligand activated transcription factors that mediate the

transcriptional effects of steroid, thyroid, and retinoid hormones (14, 66-68). Among the
dietary nutrients that act as ligands and serve as signaling molecules to regulate cellular
metabolism are oxysterols and fatty acids (15, 69, 70). These compounds directly bind to
the nuclear receptor ligand-binding domain (LBD) and induce conformational changes
to trigger the exchange of corepressors with the coactivators leading to the repression or
activation of the target genes (11, 71). Liver X receptors (LXR) are ligand activated
nuclear receptors belonging to the steroid hormone receptor superfamily that specifically
bind to and are activated by oxysterols. Both isoforms of LXR form heterodimers with
the retinoid X receptor (RXR) which then bind to specific DNA elements to regulate
gene transcription. The LXR-RXR complex exhibits basal levels of transcription in the
absence of a ligand. Upon ligand activation, LXRs act as transcription factors to regulate
the expression of genes involved in cholesterol transport, lipid metabolism, and
carbohydrate metabolism. There are two LXR isoforms: the alpha isoform is found in
metabolically active tissue such as liver, kidney whereas the beta isoform is ubiquitously
expressed (72). Although both isoforms are involved in regulating cholesterol
homeostasis, the alpha isoform is the predominant isoform that functions as a master
hepatic lipogenic transcription factor (73).
In LXRα knockout mice, the CYP7a1 gene (which is involved in cholesterol
metabolism) is down regulated, resulting in accumulation of cholesterol in the liver.
Genes involved in hepatic fatty acid biosynthesis, such as sterol regulatory element
binding protein (SREBP-1), stearoyl CoA desaturase (SCD) and fatty acid synthase
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(FAS) are also down regulated in LXRα deficient mice, and LXRβ was unable to
compensate for this loss of LXRα. In LXRβ- deficient mice, expression of the above
genes remains unaffected (74, 75). Furthermore, patients with non-alcoholic fatty liver
disease (NAFLD) and hepatitis C virus induced steatosis have elevated levels of LXRα
and its target gene involved in lipogenesis (76-78). Not surprisingly, LXRs are attractive
drug targets for the treatment of diabetes and metabolic disorders (79-81).
Although oxysterols are classical endogenous ligands of LXRs, fatty acids have been
reported to inhibit oxysterol binding to LXR. The inhibition depends on the degree of
unsaturation of the fatty acids; polyunsaturated fatty acids are more potent inhibitors of
oxysterol binding compared to monounsaturated FA suggesting that fatty acids or fatty
acyl-CoAs may directly bind LXRα (35, 82-84). Furthermore, LXRα can form a
heterodimeric pair with PPARα (43), and each of the two proteins individually binds
fatty acids (36, 85). This creates complexity in understanding and characterization of
individual signaling pathways. To differentiate the direct and indirect effects of PPAR
ligands (FA) on LXRα, it is important to quantify the binding affinities of fatty acid
binding to LXRα. The main goal of this study is to test the hypothesis that LXRα serves
as a fatty acid receptor through investigating fatty acid binding to LXRα.
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3. Materials and Methods
Purification of Recombinant hLXRα: Plasmids for full-length hLXRα recombinant
protein expression were transformed into Rosetta 2 competent cells. Protein was purified
through affinity chromatography with the GST tag and on-column digestion as described
(44). Protein concentrations were estimated by the Bradford assay (Bio-Rad, Hercules,
CA). Protein purity was determined by sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE) followed by Coomassie Blue staining and Western
blotting (44).
Reagents: Fluorescent fatty acids (BODIPY-C16 and BODIPY-C12) were purchased
from Molecular Probes, Inc. (Eugene, OR). BODIPY C12-CoA and BODIPY C16CoA were synthesized and purified by HPLC as previously described, and found to
be >99% pure and unhydrolyzed (86).
Fluorescent Ligand Binding Assays: Fluorescent ligand (BODIPY C16,
BODIPY C12, BODIPY C12-CoA or BODIPY C16-CoA) binding measurements
were performed using 0.1 µM LXRα with increasing concentrations of fluorescent
ligand in phosphate buffered saline (PBS), pH7.4.

Fluorescence emission spectra

(excitation, 465 nm; emission, 490-550 nm) were obtained at 24°C with a PC1 photon
counting

spectrofluorometer

(ISS

Inc.,

Champaign,

IL),

and corrected

for

background (protein only and fluorescent ligand only). Maximal intensities were used to
calculate the apparent dissociation constant (Kd) (86, 87). All ligand concentrations were
below the critical micelle concentrations and were delivered using ethanol as a solvent.
Displacement of Bound Fluorescent BODIPY C16-Co by Non-fluorescent Ligands:
To examine further whether fatty acids could bind LXRα directly and displace a

37

fluorescent ligand, putative ligands were assessed for displacement using recombinant
LXRα and BODIPY labeled C16-CoA in PBS, pH7.4. 0.1 µM LXRα was mixed with
0.1 µM of BODIPY C16-CoA and the maximal fluorescence intensity was measured.
The effect of increasing concentrations of fatty acids or fatty acyl CoA was measured by
quenching fluorescence of BODIPY C16-CoA at 240C. All spectra were corrected for
background as described above for BODIPY. Changes in fluorescence intensity were
used to calculate the inhibition constant (Ki) values (86, 87).
Quenching of LXRα Aromatic Amino Acid Residues by Non-fluorescent Ligands:
The direct binding of LXRα to non-fluorescent ligands was determined by quenching of
intrinsic LXRα aromatic amino acid fluorescence. LXRα (0.1 µM) was titrated with
increasing concentrations of ligand in PBS, pH7.4. Emission spectra from 300-400 nm
were obtained with a PC1 photon counting spectrofluorometer (ISS Inc., Champaign,
IL) at 24°C using an excitation of 280 nm. Data were corrected for background and
inner filter effects, and maximal intensities were used to calculate the apparent
dissociation constant (Kd) (86, 87).
Secondary structure determination: Effect of ligand binding on LXRα circular
dichroism: Circular dichroic spectra of hLXRα (0.6 µM in 600 µM HEPES pH 8.0,
24 µM dithiothreitol, 6 µM EDTA, 6mM KCl and 0.6 % glycerol) were
m o n i t o r e d in the presence and absence of fatty acids and fatty acyl-CoA (0.6 µM)
with a Jasco J-815 spectropolarimeter. Ligand stock solutions were prepared in ethanol
or KH2PO4 pH 8.0 as vehicle. Spectra were scanned from 260 to 187 nm using a
bandwidth of 2.0 nm and sensitivity of 10 millidegrees. The scan rate of 50 nm/min
using a time constant of 1 s was used. Ten scans were averaged and percent
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compositions of α-helices, β-strands, turns and unordered structures were estimated
using the CONTIN/LL program of the CDpro software package (44, 86-89).
Mammalian Expression Plasmids: hPPARα and hLXRα from 6xHis-GST-hPPARα
and 6xHis-GST-hLXRα were transferred into the multiple cloning site of pSG5
(Stratagene; BamH1-end-filled BglII) to produce pSG5-hPPARα and pSG5-hLXRα
respectively as described (44). The human sterol regulatory element binding protein 1c
(hSREBP-1c) minimal promoter (-520 to -310) containing the LXRE (90) was cloned
into the pGEM-T easy vector (Promega) and subsequently transferred into KpnI-XhoI
sites of pGL4.17 (Promega) to produce hSREBP-1c-pGL4.17. All plasmid constructs
were confirmed by DNA sequencing.
Cell culture and Transactivation assay: COS-7 cells (ATCC, Manassas, VA) were
grown in DMEM supplemented with 10 % fetal bovine serum (Invitrogen, Grand Island,
NY) at 37°C with 5% CO2 in a humidified chamber. Cells were seeded onto 24-well
culture plates and transfected with 0.4 µg of each full-length mammalian expression
vector (pSG5-hPPARα or pSG5-hLXRα) or empty vector (pSG5), 0.4 µg of the LXRE
LUC reporter construct (hSREBP1c-pGL4.17), and 0.04 µg of the internal transfection
control plasmid pRL-CMV (Promega Corp., Madison, WI) with Lipofectamine™ 2000
(Invitrogen, Grand Island, NY). Following transfection incubation, the serum-free
DMEM was added for 2 h, ligands (10 µM) were added, and the cells were
grown for an additional 20 h. Fatty acids were added as a complex with bovine
serum albumin (BSA) as described (44, 86, 89). Firefly luciferase activity, normalized
to Renilla luciferase (for transfection efficiency), was determined with the dual
luciferase reporter assays system (Promega, Madison, WI) and measured with a
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SAFIRE2 microtiter plate reader (Tecan Systems, Inc. San Jose, CA). All samples
were normalized against the sample with no ligand.
Molecular docking: In silico docking of ligands was performed using the LBD from
LXRα extracted from the crystal structure of LXRα-RXRβ complex (PDB entry 1UHL).
AutoDock Vina 1.1.2 and FlexiDock module of SYBYL-X 2.0 (Tripos, St. Louis, MO)
were used to dock ligands of interest to the LXRα LBD and to estimate the binding free
energies of receptor-ligand binding as described (89).
Statistical Analysis: Data were analyzed by SigmaPlot™ (Systat Software, San Jose,
CA) using the ligand binding macro (one site saturation). Binding curves were generated
by plotting changes in fluorescence as a function of total ligand concentration. Free
ligand concentrations for each ligand tested were determined by subtracting the protein
bound fraction from the total ligand concentration using the following equation:
Lfree= Ltotal-Lbound, where Lbound = (∆FL/∆FL max)*[Protein active].
The dissociation constant values (Kd) were generated using the free ligand
concentrations. Ki to Kd conversions were performed by using the following equation:
EC50 ligand/ [BODIPY C16-CoA] = Ki Ligand/Kd [BODIPY C16-CoA] (85-87).
One-way ANOVA was used to evaluate overall significance. All results were expressed
as means ± the standard error. The confidence limit of p < 0.05 was considered
statistically significant (44, 86, 89).
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4. Results
Protein Expression and Purification: Full-length recombinant hLXRα protein was
purified as described previously (44). The protein with a molecular mass of 51768 Da
migrated at approximately 50 kDa size on SDS-PAGE and it was estimated to be at least
85% pure (Fig. 9). Western blots using antibodies for LXRα showed that the 50 kDa
band was full-length, untagged LXRα.
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Fig.9. SDS-PAGE and Coomassie blue stained gel showing purification steps of full
length hLXRα protein using affinity chromatography. The prominent band
corresponding to 50 kDa represents untagged full-length proteins. Lane 1 (Marker),
Lane 2 (WCE= whole cell extract), Lane 3 (S=Clarified supernatant), Lanes 4, 5 (W1
and W2= Washes with lysis and ATP buffers respectively), and Lane 6 (EL= Elute
fraction after a 4 hour treatment with PreScission Protease).
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Binding of fluorescent fatty acid and fatty acyl-CoA to LXRα: Since the FA and
FA acyl CoA are not fluorescent, BODIPY derivative was conjugated to the ligands for
use in the protein-ligand binding studies. Low concentrations of BODIPY C16:0-CoA
(25nM) were used for binding experiments due to its limited solubility. BODIPY fatty
acid fluoresce only when bound to the protein. Titration of LXRα with BODIPY C12CoA or BODIPY C16-CoA resulted in increased fluorescence a t 515 nm (Fig. 10A,
10C) which saturated at 15 nM (Fig. 10B) and 32 nM (Fig. 10D) respectively. Sharp
binding profiles implied the approach of stoichiometric binding conditions. In these
instances, straight line extrapolations from the low ligand concentration portion of the
binding and the high ligand concentration portion of the curve intersect at a point that
has the concentration axis value approximately equal to the concentration ligand binding
sites (91). Thus, it was determined that the percentage of active protein present in the
sample is much lower than 100 nM. Multiple titrations of LXRα with various high
affinity ligands suggested that the percentage of active protein present in the preparation
was approximately 12%.
The apparent binding constants (Kd) using free ligand concentrations were estimated
to be 4 ± 0.5 nM for BODIPY C12 CoA and 21 ± 5 nM for BODIPY C16 CoA
suggesting that BODIPY C12:0-CoA and BODIPY C16:0-CoA can bind LXRα as high
affinity ligands. Similar studies using fatty acids showed little or no changes in the
fluorescence intensity, suggesting that these molecules bound relatively weaker
compared to their CoA derivatives (data not shown). The binding of C12:0-CoA, and
not C12:0 FA, was further confirmed through using aromatic residues (Tyr/Trp) in
LXRα as intrinsic donor and BODIPY labeled ligands as the corresponding acceptor
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FRET assay. FRET was observed between LXRα protein and BODIPY C12:0-CoA, but
not C12:0 FA (Fig. S1). Taken together, our results show that BODIPY C12:0-CoA and
BODIPY C16:0-CoA can bind as high affinity ligands to LXRα.
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Fig. 10: LXRα binds fluorescently labeled saturated fatty acyl-CoA. (A) Fluorescence
emission spectra of 0.1 µM LXRα titrated with 0 (filled circles), 2.5 (open circles), 5
(filled triangles), 10 (open triangles), 30 (filled squares), 50 (open squares), and 60 nM
(filled diamonds) of BODIPY C12-CoA upon excitation at 465 nm demonstrating that
the enhanced fluorescence intensity of BODIPY C12:0-CoA is a result of direct binding
with LXRα. (B) Plot of LXRα maximal fluorescence emission as a function of total
BODIPY C12:0-CoA. (C) Corrected fluorescence emission spectra of 0.1 µM LXRα
titrated with 0 (filled circles), 5 (open circles), 10 (filled triangles), 30 (open triangles),
50 (filled squares), 90 (open squares), and 100 nM (filled diamonds) of BODIPY C16CoA upon excitation at 465 nm demonstrating that the enhanced fluorescence intensity
as a result of binding to LXRα. (D) Plot of LXR maximal fluorescence emission as a
function of total BODIPY C16-CoA.
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Binding of endogenous FA and FA-CoA to LXRα – Displacement of bound BODIPY
C16-CoA: To determine the ligand specificity of LXRα for fatty acids, FA and FA-CoA
of different chain lengths and degree of unsaturation were examined for their ability to
displace BODIPY C16:0-CoA from the LXRα ligand binding pocket. The BODIPY
C16:0-CoA-LXRα complex was titrated with increasing concentrations of nonfluorescent FA or FA-acyl CoA until the effect plateaued. The decrease in fluorescent
intensity was used to calculate the efficiency (Ki) of the non-fluorescent ligand. By
comparing the percent displacement of a variety of fatty acids or fatty acyl-CoA for a
given concentration range, the relative affinities for binding of these lipids were
estimated. Whereas decanoic acid, octanoyl-CoA, and lauroyl-CoA caused a 20-50 %
decrease in the BODIPY fluorescence (Fig. 11 B, D, F), other ligands exhibited a
smaller effect (Fig. 11A, C, E, G, H). Displacement of BODIPY C16:0-CoA by its nonfluorescent analog C16:0-CoA validates earlier concerns that ligand modifications to
render them fluorescent alter the ligand binding properties. This was confirmed through
direct binding of BODIPY C16:0 CoA and C16:0 CoA to LXRα that exhibited a slight
(two-fold) decrease in the binding affinity of the fluorescent ligand (Fig. 10 D, 12 H). Of
all fatty acids and fatty acyl-CoA tested, decanoic acid and octanoyl CoA showed the
highest degree of displacement (Fig. 11B, D). Long chain fatty acids were not able to
displace BODIPY C16:0-CoA at concentrations as high as 1600 nM, suggesting that
these ligands might either bind poorly or not at all to LXRα (Fig. S2 B, C). By
comparison, LXR agonists T-0901317 and 22 (R) Hydroxycholesterol (positive
controls) displaced the LXRα bound Bodipy C16 CoA by 30% and 50% respectively
(Fig. 11I, Fig. S2A). These results taken together suggest that LXRα preferentially binds
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medium chain fatty acyl CoA and these ligands compete to some extent for binding to
the same site on LXRα as BODIPY fatty acyl CoA. Ki values for the ligands suggest that
the binding affinities of the studied ligands are 22 (R) Hydroxycholesterol and T0901317> octanoyl-CoA> lauroyl-CoA>palmitoyl-CoA>lauric acid and decanoyl-CoA
(Supp.Table 1).
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Fig. 11: Displacement assay of BODIPY C16:0-CoA bound LXR. BODIPY C16:0CoA bound to LXRα was displaced with naturally occurring fatty acids or fatty acylCoA. The fall in fluorescence due to displacement of BODIPY C16-CoA from LXRα is
expressed as percent changes when titrated with the following ligands: (A) octanoic
acid, (B) decanoic acid, (C) lauric acid, (D) octanoyl-CoA, (E) decanoyl-CoA, (F)
lauroyl-CoA, (G) palmitic acid, (H) palmitoyl-CoA, and (I) T-0901317. Data are
presented as percent change in fluorescence intensity of BODIPY C16-CoA at 515nm
plotted as a function of ligand concentrations. All values are the average for at least
three independent determinations. Error bars represent standard errors (S.E.)
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Binding of endogenous FA and FA-CoA to LXRα – Quenching of intrinsic aromatic
amino acid fluorescence: To verify that fatty acids bind to LXRα, we tested these
ligands using an intrinsic protein fluorescence using excitation at 280 nm and emission
at 342 nm. Purified recombinant LXRα (100 nM) was incubated with medium chain
saturated fatty acids, monounsaturated long chain fatty acids, polyunsaturated fatty
acids, and the corresponding fatty acyl CoA derivatives. Titration with octanoic acid
(Fig. 12A) di d n ot result in decreased LXRα fluorescence. However, addition of
decanoic acid and lauric acid resulted in decreased fluorescence, with the maximum
change occurring at very low nanomolar concentrations (Fig. 12B, C). Interestingly,
estimation of active protein (12%) obtained through the non-fluorescent ligand binding
curves was consistent with the estimation obtained through BODIPY labeled fatty acyl
CoA binding to LXRα.
The apparent Kd values of the remaining ligands binding to LXRα were measured
and are listed in Table 1. Titration of LXRα with monounsaturated and polyunsaturated
FA yielded no significant quenching of the intrinsic fluorescence suggesting either little
or no binding (Fig. S3). Binding with T-0901317 and 25-hydroxycholesterol (positive
controls) yielded binding curves that exhibited saturation with the maximal changes in
the intensities at 10 nM and 100 nM respectively (Fig. 12I, Fig. S3L). The apparent Kd
values of unlabeled C12:0-CoA obtained from the intrinsic quenching was consistent
with the value obtained with BODIPY labeled ligand. However, the Kd values of C16:0CoA differ between the two assays (Table 1). Since quenching of intrinsic protein
fluorescence is a more direct method for the determination of binding affinity, it is a
more accurate measure of ligand binding. Despite differences between the fluorescent
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methods to measure the apparent Kd values of the ligands, our findings suggest that fatty
acids bind LXRα in the nanomolar concentration range. The observed decrease in the
intrinsic fluorescence may be a result of direct interaction of LXRα aromatic amino
acids with the ligands tested or ligand induced conformational changes bringing the
aromatic amino acids in close proximity to the ligand.
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Fig. 12: Interaction of naturally-occurring fatty acids and fatty acyl-CoA with LXRα.
Direct binding assay based on quenching of 0.1 µM LXRα aromatic amino acid
fluorescence emission when titrated with the following ligands: (A) Octanoic acid (B)
Decanoic acid, (C) Lauric acid, (D) octanoyl-CoA, (E) decanoyl-CoA (F) lauroyl-CoA,
(G) palmitic acid, (H) palmitoyl-CoA, and (I) T-0901317. Data are presented as the
change in fluorescence intensity (F0- Fi) plotted as a function of total ligand
concentration. All values represent mean ± S.E., n ≥ 3.
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Table 1. Affinity of hLXRα for non-fluorescent ligands determined by quenching of
hLXRα aromatic amino acid fluorescence (Kd) and ligand efficiencies determined by
displacement of hLXRα-bound BODIPY C16-CoA (Ki).

Ligand

Octanoic acid
Octanoyl-CoA
Decanoic acid
Decanoyl-CoA
Lauric acid
Lauroyl-CoA
Palmitic acid
Palmitoyl-CoA
T-0901317

Chain length:
double bonds
(position)
C8:0
C8:0
C10:0
C10:0
C12:0
C12:0
C16:0
C16:0

Kd protein
fluorescence
N.D.
6±1
17±8
N.D.
3±1
14±3
N.D.
6±3
3±1

Kd displacement
assay
N.D
5±1
21±6
N.D.
N.D.
12±2
N.D.
5±2
N.D.

Values represent the mean ± S.E. (n ≥ 3). ND, not determined.
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Effect of endogenous fatty acids and fatty acyl-CoAs on hLXRα secondary structure:
Ligand-induced nuclear receptors exhibit the ability of ligand to induce conformational
changes in the secondary structure of the proteins. Changes in LXRα intrinsic
fluorescence as a result of ligand binding suggested that these changes may correlate
with secondary structure changes of the protein. Circular dichroism (CD) was used to
quantitatively measure changes in the LXRα CD spectrum due to fatty acid and fatty
acyl CoA binding. Fig. 13 shows the far UV circular dichroic spectrum of LXRα in the
absence or presence of ligands tested. The LXRα spectrum exhibited a large positive
peak at 192 nm and two negative peaks at 207 and 222 nm. Quantitative analysis
using the CDPro software suggested the presence of 26% α-helical, 22 % β-structure, 20
% turns, and 32 % unordered structures in unliganded-LXRα (Table 2). In relation to the
ligand-free state, addition of fatty acids and fatty acyl-CoA caused changes in molar
ellipticity at 192 nm, 207 nm, and 222 nm (Fig. 13A-H). The calculated structure (Table
2) showed that C16:0-CoA produced an increase in content and size of the α–helix
region. No statistically significant changes were observed with other fatty acids and fatty
acyl CoA although small changes in the CD spectra were evident with C8:0-CoA,
C10:0, C12:0-CoA, and C16:0 (Fig. 13D, B, E, F, G). Changes observed with these
ligands were clearly different from those produced by the solvent. Significant changes in
β-sheet content were observed with C8:0-CoA and C10:0 in agreement with the fact that
both ligands resulted in changes in intrinsic fluorescence of LXRα. CD spectral shifts
observed with C12:0 and C16:0 were limited to turns and unordered structures (Table 2).
T-0901317, a higher affinity LXR ligand, caused a smaller shift in the CD spectrum
compared to 25-HC (Fig. 13I). Significant binding of palmitoleic acid and
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eicosapentaenoic acid to LXRα was not observed although perturbations were observed
with these ligands. No significant differences were observed with the polyunsaturated
fatty acids tested (Fig. S4, Supp. Table 2).Taken together, these results suggest that fatty
acids and fatty acyl CoA binding to LXRα causes reorganization of the protein structure
with subtle differences observed between various ligands tested.
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Fig. 13: Far UV circular dichroic spectra of LXRα in the absence (filled circles) and
presence of added ligand at a concentration of 0.6 µM: (A) octanoic acid, C8:0 (open
circles) or (D) Octanoyl-CoA, C8:0-CoA (open circles); (B) decanoic acid, C10:0
(open circles) or (E) decanoyl-CoA, C10:0-CoA (open circles); (C) lauric acid, C12:0
(open circles) or (F) lauroyl-CoA, C12:0-CoA (open circles); (G) palmitic acid, C16:0
(open circles) or (H) palmitoyl-CoA, C16:0-CoA (open circles); (I) T-0901317 (open
circles) or 25-HC (filled triangle). Each spectrum represents an average of 10 scans for
a given representative spectrum from at least three replicates.

59

Table 2. Secondary structures of hLXRα protein in the presence of fatty acids and fatty
acyl-CoAs

Ethanol
C8:0
C8:0-CoA
C10:0
C10:0CoA
C12:0
C12:0CoA
C16:0
C16:0CoA
25-HC

13.7 ± 1.7
17.2 ± 2.5

11.4 ± 1.2
12.8 ± 0.8

15.9 ± 3.9
12.6 ± 3.7

β-sheet
distort
S(d)%
8.8 ± 0
8.5 ± 0.1
8.9 ± 0.5
9.2 ±
0.1*
8.1 ± 0.8
10.5 ±
0.2
9.6 ± 0.3
9.5 ± 0.9
8.1 ± 0.7

14.7 ± 0.3**

12.9 ± 0.9

8.9 ±0.3

21.4 ± 0.1**

30.1 ± 0.4*

T0901317

12.1 ± 1.3

11.9 ±
0.3**
10.5 ± 0.6

16.8 ± 1.5

9.7 ± 0.3

21.3± 0.2**

29.4 ±
0.2**

Ligand

α-helix
regular
H(r)%
13.9 ± 0.4
14.4 ± 0.5
14.2 ± 1.1
13.6 ± 0.6
15.3 ± 2.7

α-helix
distort
H(d)%
11.9 ± 0.2
12.0 ± 0.2
11.5 ± 0.8
11.5 ± 0.1
11.7 ± 0.4

β-sheet regular
S(r)%

12.1 ± 1.6
13.9 ± 0.6

9.9 ± 0.3
11.3 ± 0.6

17.9 ± 0.6
14.5 ± 1.2

13.3 ± 0.3
12.5 ± 0.6
15.8 ± 0.5***
15.3 ± 0.5**
15.7 ± 1.5*

Turns
T%

Unordered
U%

19.6 ± 0.8
19.6 ± 0.2
19.8 ± 1.3
21.2 ± 0.1
17.7 ± 3.4

32.4 ± 1.5
32.8 ± 0.5
32.2 ± 3.1
29.0 ± 0.2
36.7.0 ± 6.4

20.5 ± 0.1*
19.9 ± 1

28.9 ± 0.4*
30.6± 1.4

22.1 ± 0.8*
18.1 ± 2.8

27 ± 2.5
35.2 ±4.8

Significant difference between hLXRα with solvent compared to the absence or
presence of fatty acids or fatty acyl-CoA (in Ethanol) determined by t-test * = P<0.05,
** = P<0.01, *** = P<0.001.
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Docking of ligands: Computational methods allow identification of novel ligands for
nuclear receptors. Molecular docking using AutoDock Vina and SYBYL Tripos was
used to investigate the steric and electrostatic complementarity between the LXRα LBD
and putative ligands. The availability of LXRα LBD crystal structure allows
employment of structure-based virtual screening of various fatty acids and fatty acyl
CoA (26). The existing structure of LXRα-RXRβ complex in the presence of T-0901317
(PDB 1UHL) was used as a template to screen putative ligands of LXRα. As a first step,
LXRα synthetic agonist T-0901317 was docked as a control to validate the docking
parameters. The theoretical docking study of ligands gave results in terms of energy and
orientation of ligands. Since SYBYL utilizes a more computationally expensive force
field method compared to the inexpensive grid-based method to estimate the binding
energies, differences in values between the two methods was not surprising. As seen in
Fig. 14D, T-0901317 fits centrally inside the ligand binding pocket with the hydroxyl
head group coordinated by hydrogen bonding to H421. This orientation of T-0901317 in
the LXRα ligand binding pocket is similar to that proposed by Svensson et al. (26).
Docking exercise performed with the fatty acids and fatty acyl CoA shows that these
ligands similarly orient themselves centrally in the ligand pocket of LXRα. The polar
head group of ligand is situated close to helix 12, and interacts with amino acids H421
and W443 of LXRα in the ligand binding pocket. Whereas lauric acid and lauroyl-CoA
ligands completely fit within the ligand binding pocket, the hydrophobic tail of stearoylCoA is not accommodated in the pocket of LXRα (Fig. 14A-C). The position of docked
ligands resembles that of T-0901317 in the LBD of LXRα as reported in the LXRαRXRβ heterodimer complex (PDB entry 1UHL) (26). The predicted binding free
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energies derived by molecular docking listed in Table 3 gave a similar rank order of
binding when compared to the apparent Kd values obtained for the fatty acids, fatty acylCoA, and T0901317.
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Fig. 14: Ribbon diagrams showing the orientation of ligands (white) (A) lauric
acid; (B) lauroyl-CoA; (C) stearoyl-CoA, and (D) T-0901317 in the ligand binding
pocket of LXRα. Amino acid residues H421 and W443 are shown in stick mode.
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Table 3. The binding free energies of the ligand binding to LXRα. The binding free
energies are in Kcal. Mol

-1

for the protein-ligand complexes as estimated by

AUTODOCK and SYBYL.

Ligand
T-0901317
Lauric Acid
Octanoyl CoA
Decanoyl CoA
Lauroyl CoA
Palmitoyl CoA
Stearoyl CoA

Auto Dock Vina
-10.8
-5.3
-9.2
-8.8
-7.9
-9.1
-1.6
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SYBYL
-2047
-1913
-2413
-2053
-2371
-2933
-2177

Effect of fatty acids and fatty acyl-CoA on transactivation of LXRE:
Transactivation assay was used to confirm the functional significance of lipid binding
to LXRα.To determine the cellular activity of fatty acids, a cell based luciferase reporter
assay was used to measure the regulation of downstream transcriptional activity of
SREBP-1c in the presence of fatty acids (varied in chain length and degree of
unsaturation). COS-7 cells were cotransfected with pSG5 empty vector, LXRα alone,
PPARα alone, or LXRα with PPARα and analyzed for transactivation of an hSREBP-1c
LXRE-luciferase reporter construct in the absence or presence of ligands (Fig. 15).
Cells were treated with ligands, and transactivation was measured as percent firefly
luciferase activity normalized to Renilla luciferase (internal control). The fold of
activation was calculated against a no ligand (ethanol) control. In cells overexpressing
only hLXRα, LXR agonist 25-hydroxycholesterol (positive control) significantly
increased transactivation by 1.5 fold. The addition of the octanoic acid, decanoic acid,
and palmitic acid resulted in no significant changes in transactivation activity (Fig. 15),
consistent with the weak binding affinity of LXRα for these ligands. Lauric acid or its
metabolite was the only fatty acid that activated the reporter expression by 2-fold. This
result is in agreement with the binding studies that show binding of lauric acid and
lauroyl-CoA to LXRα. At 10uM ligand concentration, arachidonic acid lowered
luciferase activity compared to the basal levels consistent with published data that
unsaturated fatty acids antagonize ligand dependent activation of the LXR (35, 82, 83).
The enhanced reporter activity was LXRα, not PPARα, mediated since PPARα alone or
in the presence of FA showed very little change in luciferase activity. These data suggest
that lauric acid or its metabolite fulfills the requirement of an LXRα endogenous ligand
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through which fatty acids regulate LXRα activity.
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Fig. 15: Medium chain fatty acid lauric acid or its metabolite lauroyl-CoA alter
LXRα transactivation.

COS-7 cells transfected with pSG5 empty vector, LXRα,

PPARα, both PPARα and LXRα were analyzed for transactivation of the SREBP-1cLXRE-luciferase reporter construct in the presence of vehicle or 10 µM ligands. The
y-axis represents values for firefly luciferase activity that have been normalized to
Renilla luciferase (internal control), where no ligand empty vector (pSG5) sample was
arbitrarily set to 1.

The bar graph represents the mean values (n ≥ 3) ± standard

error. * P < 0.05, ** P < 0.01, and *** P<0.0001. Asterisks denote significant
differences due to ligand as compared to no-ligand controls.
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5. Discussion:
The present work demonstrates that medium chain saturated fatty acids and fatty acyl
CoA represent high affinity ligands of LXRα that bind at physiological concentrations.
Two separate fluorescence based assays confirmed that saturated fatty acyl CoAs
binding to LXRα is specific, rather than nonspecific. Changes in aromatic amino acid
fluorescence, one of the most direct methods to study ligand induced conformational
changes, demonstrated the interactions of LXRα with fatty acids and fatty acyl CoA.
The decrease in intrinsic fluorescence of LXRα supports a change in environment in
aromatic amino acids upon binding with medium chain fatty acids and fatty acyl CoA. A
direct molecular interaction of these ligands with LXRα with well characterized
apparent dissociation constants. The deduced Kd value, determined by the intrinsic
quenching assay, of T-0901317 (3±1 nM) is in agreement with those reported in the
literature (7 nM) (92). Using the same assay, the relative affinities of fatty acids showed
that binding to LXRα occurs in the low nanomolar concentration range. Furthermore,
the apparent Kd values are close to the reported concentrations of free fatty acids present
in a cell (93). Thus, binding of fatty acids and fatty acyl CoA to LXRα occurs at
physiologically relevant concentrations.
Previously reported Kd values for LXRα ligand binding were based on the
assumption that total ligand concentration present in the sample was approximately
equal to the free ligand concentrations. Since, the protein concentrations under our assay
conditions were not below or at the determined Kd values, free ligand concentrations had
to be determined to estimate the Kd values. These corrections led to the determination of
Kd values that were lower than the previously reported values.
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Disagreement was observed between Kd values determined for palmitoyl-CoA
binding to LXRα through intrinsic quenching and fluorescent ligand binding assay. This
inconsistency may be explained by previously reported work which showed that
fluorescent ligands may have a lower affinity than their non-fluorescent counterparts due
to the presence of fluorophore (94).
The relative binding affinities of various fatty acids and fatty acyl CoA with respect
to C16:0-CoA binding through in vitro competition LXRα-binding assays were also
determined. The observed competition between the fatty acids and existing endogenous
or synthetic ligands suggests that these ligands bind at a common site. Established
LXRα ligands T-0901317 and 22 (R) Hydroxycholesterol effectively displaced bound
BODIPY C16:0-CoA in the receptor competition assay. Medium chain fatty acid
(C10:0) and fatty acyl-CoA (C8:0-CoA) successfully competed with BODIPY C16:0CoA for binding to LXRα at 100 nM and 200 nM concentrations respectively.
Incomplete displacement of BODIPY C16:0-CoA by fatty acids suggests that BODIPY
dye either interferes with the binding of competing ligands or there are two or more
binding sites in the pocket for the occupancy ligands. Long chain fatty acids, such as
docosahexaenoic acid and phytanic acid, did not displace the bound ligand. This finding
implies that long chain fatty acids or fatty acyl CoA may bind poorly or bind to a
different binding site on LXRα, as they do not compete with C16:0-CoA for receptor
binding. The literature suggests that particular fatty acids prevent binding of oxysterols
to LXRα (35, 95). This effect may be mediated through fatty acids competing with
oxysterols for the same binding site or allosterically preventing efficient binding of
oxysterols in the LXRα ligand binding pocket. The data suggest that oxysterols and long
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chain fatty acids do not share the same binding site. It remains to be investigated
whether fatty acids induce gene expression similar to LXRα ligands or enhance the
interaction of the LXRα with cofactor peptides.
The ability of fatty acids and fatty acyl CoA to induce changes in the secondary
structure of LXRα was investigated. Subtle structural changes in the α–helix content, βstructure, and turns were most likely induced after the binding of fatty acyl-CoA and
fatty acid binding to LXRα. β-sheet content, as estimated by CD at 190 nm wavelength,
was significantly altered by binding of LXRα to medium chain fatty acids and fatty acyl
CoA. Although lauric acid and lauroyl CoA binding quenches the intrinsic fluorescence
of LXRα, lauric acid alone induces a conformational change in the secondary structure.
The binding of C8:0-CoA, C10:0, and C10:0 CoA not only quenches intrinsic
fluorescence, but also induces significant conformational changes in LXRα. This finding
suggests that ligand induced exposure of the LXRα aromatic amino acids to the solvent
may not accompany large conformational changes in the overall structure. Whether
conformational changes in the secondary structure of the protein are necessary for its
transactivation activity is still unclear although evidence so far suggests that this may be
true in the context of LXRα. Furthermore, our results showed that weak binding of
LXRα to long chain fatty acids and long chain fatty acyl CoA did not affect the structure
of LXRα. Even though LCFA or long chain fatty acyl CoA did not show high affinity
binding ,changes in the CD spectra implied that very small conformational changes
occurred upon C16:1 and C20:5 binding. One possible explanation for this finding could
be non-specific binding of these ligands to various surface domains of LXRα. This
finding was not entirely unexpected since LCFA are PPAR ligands (96).
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The ligand induced changes in the LXRα CD spectra, however, did not always
correlate with the binding affinities of ligands tested. One possible explanation for this
discrepancy may be that circular dichoric spectra provide a global average of all
structural changes, and it is thus possible that changes induced in one domain
ameliorated other changes. Alternatively, certain ligands may bind non-specifically to
different regions of LXRα and cause differential changes in the overall structure of the
proteins.
The structural basis for the selective preference of LXRα for medium chain fatty
acids and fatty acyl CoA derivatives and the proposed role of these molecules as LXRα
ligands was supported through molecular docking of ligands to the LBD of LXRα. The
docking modes demonstrated that the ligand binding pocket of LXRα can easily
accommodate the medium chain fatty acyl CoA, but not the longer fatty acids. These
theoretical findings are consistent with our binding data suggesting that medium chain
fatty acids and medium chain fatty acyl CoA can fit nicely in the LXRα ligand binding
pocket. On the other hand, long chain fatty acids and the acyl chains may be too large to
fit in the ligand binding pocket of LXRα (volume of 700 A0) (26) inhibiting optimal
ligand packing.
Finally, transactivation assays demonstrated that LXRα overexpression alone shows
hSREBP-1c promoter activity in luciferase assays, presumably through binding to
endogenous RXR. Addition of a fatty acid, particularly, the medium chain fatty acid
lauric acid, caused a statistically significant increase in the luciferase reporter assay
using the hSREBP-1c promoter in Cos-7 cells. Since the levels of free fatty acids within
cells are generally thought to be low and largely bound to intracellular binding proteins,
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it is possible that lauroyl-CoA, and not lauric acid, may be the true LXRα ligand. Our
binding data agrees very well with this hypothesis. Overexpression of PPARα alone was
insufficient to activate the promoter suggesting that the transactivation activity is LXRα
mediated. Co-expression of LXRα and PPARα shows repression of transactivation
activity observed with LXRα overexpression alone. Taken together, these data support
the idea that saturated medium chain fatty acids and fatty acyl CoA are potential LXRα
agonists.
In conclusion, fatty acids bind differently to LXR alpha and have distinct effects
depending on the chain length and the extent of unsaturation. Future research may
explore the possibility that the effects of medium chain triglycerides in the treatment of
metabolic disorders may be mediated via activation of LXRα.
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CHAPTER II
EFFECT OF LIVER X RECEPTOR ALPHA LIGANDS ON LXRα-PPARα
HETERODIMERIZATION – FLUORESCENCE BASED ANALYSIS OF FULLLENGTH PROTEINS

74

1.

Abstract

Analyzing the effects of ligands on protein-protein interactions is critical for
comprehensive understanding of the activation mode of ligand activated transcription
factors. Liver X receptor α (LXRα) and peroxisome proliferator-activated receptor α
(PPARα) are members of the nuclear receptor superfamily that maintain cholesterol and
lipid homeostasis respectively. Each receptor binds to retinoid X receptor (RXR) and
specific DNA sequences located within the promoters of their target genes. No crystal
structure of LXRα-PPARα complex is available, thus limiting our understanding of how
the LBDs of these proteins might interact. Our in silico analysis through protein-protein
docking (Hex) suggests that LXRα might utilize distinct amino acid residues to interact
with each partner receptor. The aim of this study was to show that ligand binding
influences LXRα dimerization dissociation constant values. Fluorescence-based in vitro
assays were used to evaluate the effect of ligands on the relative strength of dimers
composed of full-length LXRα and PPARα. Fluorescence quenching of Cy3-labeled
PPARα as a result of binding unlabeled LXRα was first used and apparent dissociation
constants (Kd) of dimers were determined. A Forster resonance energy transfer (FRET)
- based approach was used to determine the Kd values of dimers in the absence or
presence of ligands. The values obtained were in agreement with the previous results
which confirmed that fluorescent based approaches can accurately measure LXRαPPARα binding constants. Our results demonstrated that LXRα bound PPARα with a
high affinity at low nanomolar concentrations. Exogenous LXRα ligands regulated the
strength of this interaction and induced significant changes in the secondary structure of
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the dimers. The effects of medium chain fatty acids (C10:0 and C12:0), recently
identified as novel ligands of LXRα, on LXRα-PPARα interactions were investigated
and it was found from the determined binding Kd values that C10:0 FA enhanced
whereas C12:0 weakened LXRα-PPARα interactions. Together, this study suggests that
LXRα ligand binding pocket and dimer surface are allosterically coupled and ligands
differentially modulate LXRα-PPARα interaction. The latter finding may aid in the
discovery of allosteric modulators with unique targeted therapeutic uses.
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2.

Introduction
The nuclear receptor (NR) family of transcription factors include receptors for

steroids, thyroid hormone, and other small hydrophobic molecules. NRs play important
roles in maintaining homeostasis, in growth, and development and are frequently
dysregulated in diseases (1, 8). Peroxisome proliferator-activated receptor (PPARα) and
liver X receptor (LXRα) are ligand-activated transcription factors that regulate genes
involved in fatty acid and cholesterol homeostasis. Both proteins are activated by
ligands (fatty acids and oxysterols respectively) and bind as heterodimers with the 9-cisretinoic acid receptor (RXR) to activate gene transcription. Administration of LXR
ligands in rodents exhibits anti-diabetic and anti-atherosclerotic effects confirming the
crucial role LXR plays in cholesterol metabolism. PPAR alpha activation is associated
with improved lipoprotein profile and exhibit anti-inflammatory effects in a wide range
of pathological conditions. Thus, both receptors are potential drug targets in the
treatment of metabolic disorders (97).
LXR and PPAR, like other NRs, contain a central DNA binding domain that is linked
to a relatively less conserved, multifunctional C-terminal ligand binding domain (LBD)
(43). The LBD contains binding sites for cofactors, such as corepressors and
coactivators, and provides a surface for homodimer or heterodimer formation with the
retinoid X receptor (RXR) (26) or PPAR. Heterodimer formation is highly regulated by
binding to ligands (43, 44). The three dimensional crystal structure of NR heterodimers
reveals a common architecture that shows that the ligand binding pocket is distinct from
the region that promotes protein-protein interactions (26). Ligand binding to either
receptor (LXRα or RXRα), or both is sufficient to initiate a downstream cascade of
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events resulting in gene activation or repression (15). Recent work has been done to
understand the regulation of the newly discovered heterodimer composed of LXRα and
PPARα (43, 44). In the absence of a three dimensional structure of LXRα with PPARα,
a computational model of how the two proteins might interact merits explanation. Since
the LBDs of LXRα and PPARα have been crystallized individually, they may be used as
models for computational study of their interaction. Hex docking has been proposed to
generate a list of plausible models that explores the space of possible conformations of
individual components (98). In addition, factors that influence the dimerization of these
proteins have been identified with respect to PPARα ligands (44), but the effects of
LXRα ligands on dimerization are not very well characterized.
A majority of in vitro studies have utilized truncated proteins (purified LBDs) to
investigate the binding affinities of LXRα with RXRα and PPARα (43). These studies
demonstrated that LXRα ligands (22-R HC and T0901317) and RXRα ligand (9cRA)
increased the LXRα-LBD/RXRα-LBD interaction by two to four orders of magnitude.
On the other hand, 22-R HC and PPARα ligands (WY 14643 and Bezafibrate) promoted
PPARα-LBD/LXRα-LBD interactions by one order of magnitude.

However, LBD

fragments might behave differently compared to full-length proteins in a complex; and
their binding kinetics may be dramatically different. In support of this idea, our
laboratory has reported full-length human LXRα-PPARα interaction in the presence of
fatty acids (44). We showed that long chain polyunsaturated fatty acids inhibit whereas
relatively shorter saturated fatty acids enhance this interaction. In the present study,
biophysical techniques such as fluorescent and circular dichroism spectroscopies were
used to characterize the strength of full-length LXRα-PPARα interaction in the absence
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or presence of LXRα ligands. This study demonstrated that LXRα ligands modulate
binding dissociation constants describing LXRα-PPARα dimerization and induce
conformational changes in the dimers.
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3.

Materials and Methods

Chemicals: Ligands were purchased from Sigma-Aldrich (St. Louis, MO). Cy3,
Alexa fluor 488, and Alexa Fluor 555 protein labeling kits were purchased from
Amersham Biosciences (Piscataway, NJ).
Plasmids: Expression vectors for full-length LXRα and PPARα have been previously
described (44, 86). The hPPARα coding sequence was amplified from cDNA derived
from HepG2 cells with the following primers:
5′-c ggatcc ATGGTGGACACGGAAAGCCC-3′ and
5′-c gtcgac CTATCAGTACATGTCCCTGTAG-3′.
In these and subsequent primers, lowercase represents nucleotides outside of the
PPARα open-reading frame with restriction sites underlined. The PCR product was
cloned into the pGEM-T easy vector (Promega Corporation, Madison, WI) and
subsequently transferred into the Bam HI / Sal I sites of the pGEX-6P derivative to
produce 6xHis-GST-hPPARα. Human LXRα (hLXRα) and human retinoid X receptor α
(hRXRα) were amplified from cDNA derived from HepG2 cells using the following
primers:
5′-ggatccATGTCCTTGTGGCTGGGGGCCCCTGTG-3′ and
5′-aagcttCTCGAGTCATTCGTGCACATCCCAGATCTC-3′ (hLXRα),
5′-cgaattcATGGACACCAAACATTTCCTGCCGCT-3′ and
5′-ctcgagCTAAGTCATTGGGTGCGGCGCCTCC-3′ (hRXRα).
In these and subsequent primers, the lowercase letters represent nucleotides outside
of the target sequence with restriction sites underlined. Each PCR product was cloned
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into the pGEM-T easy vector (Promega, Madison, WI) and subsequently transferred into
the BamHI–HindIII or EcoRI–XhoI sites of the pGEX-6P derivative to produce 6xHisGST-hLXRα and 6xHis-GST-hRXRα, respectively. LXRα and PPARα were expressed
as fusion proteins containing an N-terminal poly-histidine GST tag. cDNA encoding full
length hLXRα and hPPARα proteins were cloned into a pGEX-6P-3 bacterial expression
vector (GE Healthcare), which contains a His and a GST tag upstream of the protease
cleavage site (44, 86). All plasmid constructs were confirmed by DNA sequencing.
Protein expression: Plasmids for recombinant LXRα and PPARα protein purification
were transformed into Rosetta 2 competent cells and used to produce full-length hLXRα
and hPPARα proteins Cultures were grown overnite (16h) at 30oC in LB broth
containing ampicillin to OD600 = 1.2. Protein expression was induced with
isopropylthiogalactoside (Sigma, final concentration of 0.1 mM) at 16oC and cultures
were allowed to grow for another 4h. Bacteria were pelleted by centrifugation at 8500
rpm for 10 min (Beckman Coultor rotor JA 10) and the pellets were frozen at -80oC.
Recombinant protein purification: Frozen pellets were solubilized in lysis buffer (20
mM Tris, pH 8.0, 300 mM NaCl, 10% glycerol, 1 mM EDTA, pH 8.0 and 1 mM DTT).
The resuspension was sonicated six times (30s each) and centrifuged at 12000 rpm for
30 min (Beckman Coultor rotor JA 25.50). Supernatant containing His-GST-tagged
protein was applied to a GST column equilibrated in lysis buffer. The GST tag was
cleaved by an on-column digestion using PreScission protease. The released proteins
were eluted, concentrated, and analyzed using SDS-PAGE and western blotting with
specific antibodies (44, 86).
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Hex docking of LBDs of LXRα with PPARα: The docking analysis was carried out
using Hex 8.0.0. Hex explores ways in which two molecules fit together and dock to
each other based on shape or charge complementarity (98). LXRα LBD (extracted from
PDB entry 1UHL) and PPARα LBD (extracted from PDB entry 1K7L) were treated as
receptor and ligand respectively for docking. Energy minimized receptor files were
prepared using SPDBV and uploaded as inputs into HEX. To dock, the locations of the
molecular centroids and the relative orientations of proteins with respect to the
intermolecular axis were considered. Water molecules and any other hetero molecules
were removed prior to docking. Based on the energy minimization, the best pose of the
docked complex was selected.
Protein-protein binding assay- Recombinant PPARα was fluorescently labeled with
Cy3 dye using Fluorolink-antibody Cy3 labeling kit (Amersham Biosciences,
Pittsburgh, PA). Absorbance measurements were used to characterize the protein-dye
conjugates. Emission spectra (560-650 nm) of 25 nM Cy3-labeled PPARα dissolved in
PBS were recorded upon excitation at 550 nm with increasing concentrations of
unlabeled LXRα in a Cary Eclipse fluorescence spectrophotometer at 240C. The spectra
were corrected for background (buffer, solvent, and protein alone), and the maximal
intensities were recorded. To determine the effects of ligands on LXRα-PPARα
interaction, the experiments were repeated in the presence of each ligand at a
concentration determined by their binding affinities. The dissociation constants (Kd)
were obtained after correcting for bound protein and inactive protein as described above
and reported previously (44). Binding constants were extracted from binding curves by
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nonlinear regression analysis using the ligand binding function in Sigma Plot (SPSS
Inc., Chicago, IL) (44).
Forster resonance energy transfer (FRET) - To confirm the previous results,
recombinant proteins were labeled with fluorescent dyes comprising a FRET pair (Alexa
Fluor488/555 dyes). FRET develops when an excited donor fluorophore is in close
enough proximity to an acceptor fluorophore so that energy transfer can occur. This
technique allows for quantitative measurement of protein interactions and can be
demonstrated by the enhanced emission from acceptor or by the decreased emission
from the donor. The amount of transferred energy increases exponentially with
decreasing distance between fluorophores, while it drops to virtually zero when the
distance becomes greater than 10 nm (99). Primary amines of the purified recombinant
proteins (LXRα and PPARα) are potential labeling targets through the use of protein
labeling kits (GE Healthcare Amersham). The dye: protein molar ratio was maintained
at 1:1 suggesting the presence of probably one dye label per protein. Since each protein
carried approximately a single fluorescent dye, the signal was expected to be
proportional to the number of protein-protein binding interactions (99). Alexa Fluor 488labeled LXRα was kept at a constant concentration of 25 nM in PBS, pH 7.4. The
sample was excited at 488 nm and emission spectra (500-670 nm) were recorded with
increasing concentrations of Alexa Fluor 555-labeled PPARα in a Cary Eclipse
fluorescence spectrophotometer. The slit widths for the excitation and emission
monochromators were 5 nm each, and the titrations were performed at 240C. The spectra
were corrected for background (buffer, solvent, and each protein individually) and
decrease in the donor’s emission was monitored. To determine the effect of ligands on
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LXRα-PPARα interactions, the experiments were repeated in the presence of 2.5 to 200
nM of each ligand. This range of ligand concentration was chosen since published data
from our laboratory suggested that LXRα and PPARα bind endogenous or synthetic
ligands within the concentration range of 2-30 nM. Protein-protein binding curves were
generated using the decrease in the donor emission plotted as a function of acceptor
concentration. Apparent dissociation constants were estimated from the titration curve as
described (44, 99).
Circular dichroism (CD) - A hallmark of nuclear receptors is the ligand induced
conformational changes in the secondary structure of the protein. In addition,
interactions with partner receptors tend to cause conformational changes upon binding
(85-89, 96). Circular dichroism (CD) is a spectroscopic technique for studying proteinprotein and protein-ligand interactions in solution. Proteins contain a number of
chromophores that give rise to CD signals. The CD spectrum can be analyzed to
estimate the content of regular secondary structural features such as alpha helices (αhelix) and beta sheets (β-sheet) (88). Each of these secondary structures gives rise to a
characteristic shape and magnitude of CD spectrum. In the far-UV spectral region (240180 nm), the chromophore is the peptide bond, and the signal arises when it is located in
a regular, folded environment. While changes at 222 or 218 nm can give an estimate of
increase in α-helical or β-structure content, more precise estimates of changes in
secondary structure accompanying protein-protein or protein-ligand interactions can be
made utilizing the previously described software (88). CD spectra of protein complexes
were obtained by use of a Jasco J-815 CD spectrometer as described previously (85-89).
Circular dichroic spectra of a mixture of PPARα and wild-type LXRα (0.2 µM each in
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30 mM NaCl, 2 mM Tris, pH 8.0, 0.5 µM EDTA, 0.04% glycerol at 220C in a 1mM
cuvette) were measured in the presence and absence of ligands with a J-815
spectropolarimeter (Jasco Inc., Easton, MD). Spectra was recorded from 260 to 187 nm
with a bandwidth of 2.0 nm, sensitivity of 10 millidegrees, scan rate of 50 nm/min and a
time constant of 1 s. Ten scans were averaged for analysis of percent compositions of αhelices, β-strands, turns and unordered structures using the CONTIN program of the
CDpro software package (85-89, 96).
To determine if physical interactions between LXRα and PPARα were altered upon
ligand binding to either protein, CD spectra were obtained from individual proteins (0.4
uM), as well as protein combinations, in the absence or presence of ligands. Replicate
spectra were recorded five times over the far-UV region from 186 to 260 nm with a 2
nm bandwidth, 10 millidegree sensitivity, 50 nm/min scan rate, and 1 s time constant.
CD spectra of each receptor with ligand was compared to the spectrum for that receptor
in the absence of ligand to determine ligand-induced conformational changes in the
receptor. The CD spectra of each heterodimeric pair with ligand was compared to (a) the
same receptor-receptor pair in the absence of ligand (b) the calculated average of the
spectra of the individual receptors in the absence of ligand, and (c) the calculated
average of the spectra of the individual receptors each in the presence of ligand. The CD
spectrum of the mixed proteins was compared to a theoretical spectrum of proteins as
described (44).
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4.

Results

Purification of recombinant proteins: Bacterial expression of highly soluble and
stable His-GST tagged full-length LXRα and PPARα proteins was detected by
immunoblotting

(data

not

shown).

Subsequent

purification

through

affinity

chromatography, electrophoresis, and immunoblot of purified PPARα and LXRα
proteins showed major protein bands at molecular weight of approximately 52 kDa and
50 kDa respectively (Fig. 16). Immunoblot using anti-PPAR and anti-LXR antibodies
recognized the bands confirming that the preparation contained PPARα and LXRα
proteins. Assessment of the folding of the recombinant purified proteins into native
structure was monitored by circular dichroism spectroscopy
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Fig. 16: SDS-PAGE and Coomassie blue staining of purified full-length hPPARα (left)
and hLXRα (right) proteins showing the relative purity. The prominent bands
correspond to 52 kDa and 50 kDa represent untagged full-length PPARα and LXRα
respectively proteins. Anti-PPARα and anti-LXRα antibodies were used to perform
Western blot analysis to identify the purified recombinant proteins.
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Hex docking of LBDs of LXRα and PPARα: Docking resulted in the generation of
possible docking conformations along with model scoring. The most plausible
conformations yielded a favorable binding energy value (-590 kcal/mol) and a putative
interface between the LBDs of LXRα and PPARα. A Hex based scoring function
identified near-native crystallographic orientations. The top 10 scoring poses generated
by the docking program were assessed for protein-protein interactions. The resultant
interface was determined based on the existing knowledge of the location of interdimer
protein binding sites. Most of the interactions predicted by this model occurred between
the C-terminus of LXRα and the C-terminus of PPARα. Interestingly, LXRα helix 10
residues, located at the interface of the reported LXRα-RXRβ crystal structure, are
positioned differently in LXRα-PPARα model (Fig. 17). This suggests that LXRα might
utilize distinct and separate juxtapositions to form interactions with RXR and PPARα.
The possibility that all three proteins may bind to form a trimeric complex can be
excluded based on the body of evidence gathered from the reported crystal structures
and gel filtration assays. These studies demonstrated that whereas RXRα is capable of
forming tetramers and heterodimers, PPARα and LXRα exist as dimeric complexes with
each other and with RXRα. In addition, LXRα has the ability to form homodimers that
implies an unknown functional consequence.

88

89

Fig.17. Positions of LXRα and PPARα residues proposed as participating in proteinprotein interactions derived from Hex docking of LXRα LBD (extracted from PDB
1UHL) with PPARα LBD (derived from PDB 1K7L). Residues are depicted in white.
Helices 9 and 10 of LXRα (shown in light orange and dark orange respectively) have
been partly removed to provide a better view of the hypothetical LXRα-PPARα
interface.
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Fluorescence monitoring of LXRα-PPARα association: We first examined the
association of purified full-length proteins, LXRα with PPARα, in vitro using
recombinant hPPARα fluorescently labeled with Cy3 dye. Fluorescence emission of
Cy3-labeled PPARα was measured in the presence or absence of unlabeled LXRα. Fig.
18 shows concentration dependent fluorescence changes induced by LXRα in the
presence and absence of exogenous ligands. Quenching of Cy3 dye occurred as a result
of a conformational change induced in Cy3-PPARα due to binding with LXRα. The
observation that saturation occurred at 8-13nM suggested that the fraction of active Cy3PPARα protein present in the sample is probably lower than 25 nM. The saturable curve
yielded an apparent dissociation constant (Kd) of 7±3 nM using a single site model
indicating a high affinity binding between LXRα and PPARα. Addition of saturating
concentrations of ligands differentially altered the binding dissociation constants of
LXRα-PPARα interaction. The Kd for the LXRα-PPARα dimer affinity were determined
to be 25±5 nM (with T-0901317), 11±2 nM (with 25-HC), and 93±43 nM (with C16:0
FA).

91

T-0901317

A

Solvent

4000

4000

2000

2000
Kd= 7±3 nM

0
0

50

0

100

150

200

250

Kd =25±5 nM
0

300

20

40

[LXR], nM

60

80 100 120 140 160

[LXR], nM

25-HC

C

6000

D

C16:0 FA

F0-F (a.u.)

6000

F0-F (a.u.)

B

6000

F0-F (a.u.)

F-F0 (a.u.)

6000

4000

4000

2000

2000

0
0

50

100

Kd =93±43 nM

0

Kd =11±2 nM
150

200

250

[LXR], nM

0

50

100

150

[LXR], nM

92

200

250

Fig. 18: Fluorescent protein-protein binding assays of 25 nM Cy3-labeled hPPARα
titrated against increasing concentrations of unlabeled hLXRα in the absence or presence
of ligands. The change in fluorescence intensity of 25 nM Cy3-labeled hPPARα was
titrated with increasing concentrations (0-250 nM) of hLXRα in the presence of (A)
solvent, saturating amount of (B) T-0901317, (C) 25-HC, and (D) C16:0 FA. Values
represent means ± the standard error (n = 3-5).
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The effect of ligands on the FRET between LXRα heterodimers: Alexa fluor dye
labeled proteins were utilized to perform FRET and determine the association of dimers
composed of LXRα and PPARαas detected by the emission at 519 nm (Fig. 19A). Since
there is minimum overlap of acceptor emission at the donor maximum emission (519
nm), we chose to monitor FRET as a decrease in donor intensity and not an increase in
acceptor intensity (580 nm). The apparent Kd for the LXRα-PPARα dimer in the absence
of ligand was 8±3 nM (Fig. 19B). By comparison, the Kd value for LXRα-RXRα
binding was also determined to be in the low nanomolar concentration range suggesting
that both LXRα-PPARα and LXRα-RXRα are high-affinity binding complexes (data not
shown). Furthermore, titration experiments allowed us to estimate ligand concentrations
required to fully saturate the proteins. Ligands were assessed for their effects on
dimerization: synthetic LXR agonist T-0901317, endogenous LXR agonist 25-HC, a
PPARα agonist C16:0 FA, and MCFA. All fluorescence based experiments were
conducted under saturating ligand concentrations (1 uM for T-0901317, and 10 uM for
25-HC and FA). Our data suggest that the apparent Kd values for dimerization were not
similar with all the ligands tested. Compared with the dimers in the absence of ligand,
different ligands affected the apparent Kd values by factors ranging from 0.16- to 3-fold.
Synthetic agonist T-0901317 increased the heterodimerization Kd by 1.25-fold while the
endogenous ligand 25-HC increased the heterodimerization Kd by 1.62-fold. C10:0 FA
decreased the heterodimerization Kd by 0.16-fold while C12:0 and C16:0 increased the
heterodimerization Kd by 3-fold and 2.25-fold respectively (Fig. 19C-G). The statistical
significance of differences using the Student’s t-test did not exhibit statistically
significant differences between samples treated with solvent and various ligands. A
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possible explanation could be that ligands tested might induce subtle structural changes
to be detected by intramolecular FRET, which is most sensitive to changes in distance
when fluorophores are between 10-100 A0 apart. Interestingly, T-0901317, compared
with all the other ligands, binds LXRα with the highest affinity but this effect is not
similar to the change in affinity between LXRα and PPARα.. Taken together, our data
demonstrated that classical LXRα ligands increased the Kd values whereas PPARα
ligand C16:0 and the newly identified LXRα ligand C10:0 decreased the Kd value.
Based on previous findings, it is safe to speculate that distinct conformational changes at
the dimer interface induced by ligand binding might modulate the dimerization
properties possibly through rearrangement of critical interface residues.
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Fig. 19: Ligands modulate the binding dissociation constants of LXRα-PPARα
interaction. FRET from 25 nM donor Alexa fluor 488-labeled LXRα to acceptor Alexa
fluor 555-labeled PPARα was detected as quenching of Alexa fluor 488 fluorescence
emission (near 519 nm). (A) Emission spectra of Alexa fluor 488-labeled LXRα upon
excitation at 488 nm in the absence or presence of increasing concentrations of Alexa
fluor 555-labeled PPAR. Plot of the average change in maximal fluorescence intensity at
519 nm (F0-F) of Alexa fluor 488-LXRα as a function of Alexa fluor 555-PPARα in the
presence of (B) solvent, (C) T-0901317, (D) 25-HC, (E) C10:0 FA, (F) C12:0 FA, and
(G) C16:0 FA. Values represent the means ± SE, n = 3-5. FRET, Forster resonance
energy transfer.
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Circular dichroism: To investigate the possibility of the ligands causing
conformational changes in the LXRα-PPARα dimer, circular dichroism was used to
estimate the secondary structure of proteins under various conditions. As seen in Fig.
20A, the CD spectrum of the individual proteins are different, yet qualitatively similar
with PPARα, which exhibits a higher alpha helical content. For the equimolar mixture of
the two proteins, the experimentally observed spectrum is different from the spectrum
obtained by averaging the spectra of individual proteins (based on the assumption that
no interaction exists between the proteins) (Fig. 20B). The changes in the secondary
structure composition of the proteins indicate that there is a direct interaction
accompanied by conformational changes. To determine the effect of ligands on this
interaction, the CD experiment between LXRα and PPARα was repeated in the presence
of ligands for LXRα (T-0901317, 25-HC, and fatty acids) and PPARα (C16:0 FA). The
presence of T-0901317 or C16:0 resulted in maximal changes at both the 210 and 222
nm minima in the circular dichroic spectra whereas the presence of 25-HC or C12:0
produced small changes in the spectra (Fig. 20 C, D). This observation suggests that
ligands differentially affect LXRα-PPARα interactions consistent with previous
observations that showed that binding of each ligand resulted in a slightly different
LXRα conformational change. The changes in CD may be interpreted in terms of
differences between protein structure especially with respect to α–helix content as
measured at 210 and 222 nm.
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Fig. 20: Circular dichroic spectra of hLXRα and hPPARα proteins. (A) Circular dichroic
spectra of 0.4 uM hLXRα (filled circles) or 0.4 uM hPPARα (open circles). (B)
Experimentally observed circular dichroic spectra of a mixture of 0.2 uM hLXRα and
0.2 uM hPPARα (obs, open circles) compared to the calculated average of the
individually obtained hLXRα and hPPARα proteins (Calc, closed circles) demonstrating
interactions between proteins. Circular dichroic spectra of a mixture of hLXRα and
hPPARα proteins in the presence of ligands (C) T-0901317 (open circles) or C12:0 FA
(filled triangles), and (D) 25-HC (open circles) or C16:0 FA (filled triangles). Each
spectrum is representative of an average of ten scans taken from at least three replicates.
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5.

Discussion
Dimerization of LXRα, like other nuclear receptors, is a key step in the cascade of

events leading to the activation of ligand activated transcription factors. In this study, we
have shown that ligand binding influences protein binding kinetics of LXRα. We
utilized an in silico molecular docking approach combined with fluorescence
spectroscopy to characterize LXRα-PPARα interactions. The effects of ligands on
LXRα-PPARα dimerization was determined through (1) monitoring the quenching of
the fluorophore covalently attached to the protein, and (2) quantifying secondary
structural changes induced in the dimer. Our data suggest that most ligands tested, with
the exception of C10:0 FA, destabilized LXRα-PPARα interaction. Whether these
ligands concomitantly strengthen LXRα-RXRα dimerization or coregulator interactions
has yet to be determined. Furthermore, we observed a range in fold changes in the ligand
induced Kd values for LXRα-PPARα protein-protein interactions. Together, our data
suggest that binding of ligands differentially affect the overall LBD conformation to
regulate the protein binding dissociation constants of LXRα. This may have implications
in determining the off rate of the LXRα-PPARα dimer in the bound state to its response
element and eventually the affinities with which the cofactors bind to the liganded
complex. Improved understanding of influences of ligand binding on heterodimer
formation may aid development of drugs that could exhibit selectivity in modulating the
activities of particular LXRα oligomers.
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CHAPTER III

DEFINING REQUIREMENTS FOR HETERODIMERIZATION OF THE HUMAN
LIVER X RECEPTOR ALPHA MEDIATED HETERODIMERIC COMPLEXES
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1.

Abstract
Liver X receptor alpha (LXRα) plays a critical role in the maintenance of lipid and

cholesterol homeostasis. Ligand binding and dimerization with retinoid X receptor
(RXR) or peroxisome proliferator-activated receptor (PPAR) is required for forming
active DNA binding complexes leading to gene regulation. Structure based prediction and
solvent accessibility of LXRα LBD shows that residues H383, E387, H390, L414, and
R415 which are located in helices 9 and 10 may be critical for mediating protein-protein
interactions. In this study, LXRα interface residues were individually mutated to
determine their effects on ligand binding, protein-protein association, subcellular
localization, and transactivation activity. Ligand binding studies showed that T-0901317
did not bind to mutants L414R and R415A, but binding to 25-HC was retained.
Fluorescent protein-protein binding assay demonstrated a decreased affinity of L414R for
RXRα, but not for PPARα. Binding of LXRα mutants L414R or R415A with PPARα
resulted in little or no conformational changes in the secondary structure of the dimers as
determined by circular dichroism spectroscopy. Cell based bimolecular fluorescence
complementation assays exhibited a weak fluorescent signal for L414R-RXRα, but
strong fluorescent signal for the L414R- PPARα dimers. Furthermore, all LXRα mutants
exhibited either lower or similar levels of ligand dependent luciferase activity driven by
the SREBP-1c promoter. Taken together, our study demonstrates that charge reversal at
the interface surface alters selectivity of LXRα dimerization, ligand binding, and reduces
the ligand-dependent transactivation activity in a promoter-dependent manner.
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2.

Introduction
Nuclear hormone receptors PPARα and LXRα are ligand activated transcription

factors that are activated by fatty acids and oxysterols respectively (1, 66). These
receptors act as sensors of elevated levels of fatty acids and cholesterol derivatives via the
receptor ligand binding domain (LBD) to regulate the expression of genes involved in
controlling cholesterol and lipid metabolism (74, 100). PPARα and LXRα can
heterodimerize and each also can dimerize with retinoid X receptor (RXR) with high
affinities. The corresponding dimers are the functionally active forms of these receptors
(43). Due to the crucial roles of these receptors in maintaining a constant level of lipids in
cells, PPARα and LXRα represent interesting targets for the development of
pharmacological compounds in the treatment of metabolic disorders (101). Drugs
targeting these receptors exhibit anti-atherogenic, anti-inflammatory, and anti-diabetic
effects. These effects are also associated with elevated levels of plasma triglycerides due
to upregulation of master lipogenic enzyme SREBP-1c (90, 102). Thus, there is an
interest in investigating regulation of the PPARα-LXRα heterodimer to explore an
alternative strategy for the pharmacological manipulation of PPARα and LXRα.
Both nuclear receptors have two well-structured domains, a central DNA binding domain
and a C-terminal LBD (14). In addition to mediating receptor dimerization, the LBD
performs a number of functions such as ligand binding, recruitment of coactivators,
transcriptional activation, and repression (103-105) Inspection of the crystal structure of
LXRα-RXRβ LBDs (PDB entry 1UHL) shows that the LXRα LBD interface is made up
of amino acid residues in helices 9 and 10 (26). Residues lining these helices provide the
locus for the majority of heterodimerization or homodimerization interaction. In
particular, amino acid residues H383, E387, and H390 (helix9) and L414 and R415
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(helix10) are located on the surface of LXRα and undergo significant changes in the
accessible surface area upon receptor dimerization (26). Critical determinants of LXRα
dimerization have not been characterized yet and variants of LXRα that exhibit selective
dimerization or ligand binding properties are unknown.
Previous work suggests that mutations have the ability to confer selectivity in protein
binding; RXRα mutants (A416D, R421L, and A416K) exhibit selectivity in binding with
thyroid hormone receptors and retinoid acid receptors (106). Although similar studies in
the LBD of LXRα have not been conducted, mutation at R415 to A was found to lack
ligand dependent transactivation activity in the context of the ADH promoter when
challenged with T0901317 (45). This suggests that residue R415 may stabilize LXRαRXR complexes, thus it is likely that loss of interactions between R415 and
corresponding residues on RXR would abolish or disorganize dimerization. In addition to
causing perturbations in the dimer formation, LXRα mutation R415A may have longrange structural and functional consequences. Consistent with this observation, I
hypothesized that charge reversal of key residues at LXRα interface may provide
selectivity in the choice of heterodimer binding and hence downstream gene regulation.
To test our hypothesis and to investigate the effects of mutating interface residues on
LXRα function, individual amino acid residues were mutated at putative protein-protein
contact points of LXRα and the effects on dimerization, ligand binding, and
transactivation activity were measured.
Single point mutations in the LXRα LBD were generated using site-directed
mutagenesis and the apparent dissociation constants (Kd) of PPARα -LXRα interactions
of mutant proteins relative to wild-type were measured. Circular dichroism (CD) was
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applied to study (a) the effect of mutations alone on LXRα secondary structure, and (b)
the conformational changes induced in the dimers due to protein-protein binding.
Bimolecular complementation assays demonstrated that LXRα mutant, L414R, is
selectively impaired in dimerization with RXRα but not with PPARα. A previously
identified LXRα mutant, R415A, exhibited intact dimerization but showed selective loss
in ligand binding to T0901317. Molecular modeling was performed to visualize the
orientation of ligands in the LXRα ligand binding pocket and it showed differences
between the positioning of ligands between wild-type and mutant receptors consistent
with the previous results. Finally, a transactivation assay showed that LXRα L414R
lacked transactivation activity when tested in the context of SREBP-1c promoter. On the
other hand, LXRα R415A behaved similar to wild-type LXRα in transactivation activity
in the context of SREBP-1c promoter, but exhibited lower activity on ApoA1 promoter.
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3.

Materials and methods
Chemicals: All ligands were purchased from Sigma-Aldrich (St. Louis, MO). CyTM3

Ab labelling kit was purchased from GE Healthcare. BiFC cloning vectors pBiFC-VN173
(pFLAG-Venus 1-172), pBiFC-CN173 (pFLAG-Venus 1-172), and pBiFC-CC155
(pHA-ECFP 155-238) were supplied by Dr. Chang-Deng Hu (Purdue University) (107).
Mutagenesis and purification of recombinant mutant hLXRα proteins: The
purification of recombinant wild-type 6xHis-GST-hLXRα and 6xHis-GST-hPPARα
proteins have been described earlier. LXRα mutant proteins were generated through
overlap PCR of 6xHis-GST-hLXRα using the following primers:

LXR H383E

Forward 5'- AGAGGCTGCAGGAGACATATGTGGA -3'
Reverse 5'- TCCACATATGTCTCCTGCAGCCTCT -3'

LXR E387Q

Forward 5'- CACACATATGTGCAAGCCCTGCAT -3'
Reverse 5'- ATGCAGGGCTTGCACATATGTGTG

LXR H390E

Forward 5'- GAAGCCCTGGAAGCCTACGTC -3'
Reverse 5'- GACGTAGGCTTCCAGGGCTTC -3'

LXR L414R

Forward 5’-CTGGTGAGCCGCCGGACCCTG-3’
Reverse 5’-CAGGGTCCGGCGGCTCACCAG-3’

LXR R415A

Forward 5’-CTGGTGAGCCTCGCGACCCTG-3’
Reverse 5’-CAGGGTCGCGAGGCTCACCAG-3’

The PCR products containing EcoRI-HF and NotI-HF sites were used to replace wildtype LXRα with the mutant LXRα PCR fragment in the appropriate vectors. The
presence of single point mutations was confirmed by DNA sequencing. Plasmids were
then transformed into Rosetta 2 competent cells and used to produce recombinant mutant
full-length hLXRα proteins through affinity chromatography as described for hPPARα
and wild-type hLXRα (44, 86, 89). Protein concentration was determined by the Bradford
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assay (Bio-Rad, Hercules, CA) and by absorbance spectroscopy using the molar
extinction for the protein. Protein purity was determined by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE), followed by Coomassie Blue staining.
Quenching of end o ge nou s f l uo r e s c e nc e o f M ut a nt LXRα by Ligands: The
direct binding of LXRα mutant recombinant proteins to non-fluorescent ligand T0901317 was determined by quenching of intrinsic LXRα aromatic amino acid
fluorescence. Mutant LXRα (0.1 µM) was titrated with increasing concentrations of T0901317 in PBS, pH7.4. Emission spectra from 300-400 nm were obtained at 24°C upon
excitation at 280 nm with a PC1 photon counting spectrofluorometer (ISS Inc.,
Champaign, IL).

Data were corrected for the bound protein, active protein present,

background and inner filter effects, and maximal intensities were used to calculate the
apparent dissociation constant (Kd) values as described (86, 89).
Circular Dichroism Spectroscopy: Circular dichroism was used to examine changes in
the secondary structure upon heterodimerization of hPPARα with each of the mutant
hLXRα proteins. Briefly, CD spectra of protein complexes were obtained by use of a
Jasco J-815 CD spectrometer. Circular dichroic spectra of a mixture of PPARα and
wild-type or mutant LXRα (0.2 µM final concentration each in 30 mM NaCl, 2 mM
Tris, pH 8.0, 0.04% glycerol buffer) were measured in the presence and absence of
ligands.

Spectra was recorded from 260 to 187 nm with a bandwidth of 2.0 nm,

sensitivity of 10 millidegrees, scan rate of 50 nm/min and a time constant of 1 s. Ten
scans were averaged for percent compositions of α-helices, β-strands, turns and
unordered structures with the CONTIN program of the CDpro software package (44, 86,
88, 89). The CD spectrum of the mixed proteins was compared to a theoretical spectrum
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of combined but noninteracting proteins. The theoretical spectrum was calculated by
averaging the spectra of each protein in the mixture analyzed separately at a
concentration equal to that in the mixture as described (44).
Protein-protein binding experiments- Recombinant PPARα was fluorescently labeled
with Cy3 dye using Fluorolink-antibody Cy3 labeling kit (Amersham Biosciences,
Pittsburgh, PA) as described (44). Emission spectra (560-650 nm) of 25 nM Cy3-labeled
PPARα were recorded in PBS, pH 7.4 upon excitation at 550 nm with increasing
concentrations of unlabeled LXRα in a Cary Eclipse fluorescence spectrophotometer at
240C. The spectra were corrected for background (buffer, solvent, and protein alone),
and the maximal intensities were recorded. To determine the effects of ligands on LXRαPPARα interaction, the experiments were repeated in the presence of each ligand at a
concentration determined by their binding affinities. Protein-protein binding curves were
analyzed by nonlinear regression analysis using the ligand binding function in Sigma Plot
(SPSS Inc., Chicago, IL). The apparent dissociation constant (Kd) values were obtained
as previously described (44).
Bimolecular Fluorescence Complementation Assay (BiFC) for Visualization of
Dimers in Living Cells- Plasmids encoding full-length 6xHis-GST hPPARα, 6xHis-GST
hLXRα, and 6xHis-GST hRXRα were digested with BamH1-HF/Not1-HF or
EcoR1/Not1 and ligated into pBiFC vectors to generate Venus-hPPARα, ECFP-hLXRα,
and Cerulean-hRXRα plasmids. All constructs were verified by DNA sequencing. COS-7
cells were grown to 50-70% confluence in DMEM supplemented with 10% FBS at 37oC
with 5% CO2 in a humidified chamber. Cells were seeded onto Lab-Tek chambered cover
glass and transfected with 0.7 µg of each BiFC plasmid using Lipofectamine 2000. The
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growth media and transfection reagent were replaced with serum-free media twenty-four
hours after transfection and allowed to grow for additional 20-24 hours before image
acquisition using a fluorescence microscope (107).
Molecular Docking- The LBD of LXRα was extracted from the crystal structure of
LXRα-RXRβ (PDB entry 1UHL) using SPDBV (26). The mutant LXRα files utilized as
input for docking were prepared using AutoDock Tools and subjected to energy
minimization. Docking of T-0901317 to the LXRα LBD was performed using AutoDock
Vina 1.1.2 and FlexiDockTM module on SYBYL-X 2.0 as described (89). The output
generated consisted of docking poses and binding energies that were ranked in the order
of the most favorable to the least favorable binding energy.
Mammalian Expression Plasmids: The generation of pSG5-hPPARα and pSG5hLXRα plasmids has been described (44). Mutant hLXRα mammalian expression
plasmids were generated by subcloning MscI-XhoI hLXRα mutant fragment from
6xHis-GST hLXRα into MscI-XhoI site of pSG5-hLXRα. The human sterol regulatory
element binding protein 1c (hSREBP-1c) minimal promoter (-520 to -310) (90)
containing the LXRE was cloned into the pGEM-T easy vector (Promega) and
subsequently transferred into KpnI-XhoI sites of pGL4.17 (Promega) to produce
hSREBP-1c-pGL4.17. The human ApoA1 promoter was amplified with the following
primers: tggtaccAGAGGTCTCCCAGGCTAAGG and
cgaattcGCAGTAACCTCTGCCTCCTG.
The PCR product was cloned into the pGEM-T easy vector and subsequently
transferred into pGL4.17 to produce hApoA1-pGL4.17. All constructs were verified by
DNA sequencing.
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Cell culture and Transactivation assay: COS-7 cells (ATCC, Manassas, VA) were
grown in DMEM supplemented with 10 % fetal bovine serum (Invitrogen, Grand Island,
NY) at 37°C with 5% CO2 in a humidified chamber. Cells were seeded onto 24-well
culture plates and transfected with 0.4 µg of each full- length mammalian expression
vector (pSG5-hPPARα, pSG5- wild-type or mutant hLXRα or pSG5-hRXRα) or empty
plasmid (pSG5), 0.4 µg of the LXRE LUC reporter construct (hSREBP-1c) or hApoA1,
and 0.04 µg of the internal transfection control plasmid pRL-CMV (Promega Corp.,
Madison, WI) with Lipofectamine™ 2000 (Invitrogen, Grand Island, NY). Following
transfection incubation, medium was replaced with serum-free medium for 2 h,
ligands (10 µM) were added, and the cells were grown for an additional 20 h.
Firefly luciferase activity, normalized to Renilla luciferase (for transfection efficiency),
was determined with the dual luciferase reporter assays system (Promega, Madison, WI)
and measured with a SAFIRE2 microtiter plate reader (Tecan Systems, Inc. San Jose,
CA). The sample were normalized against the sample with no ligand (44).
Statistical Analysis: Data were analyzed by Sigma Plot™ (Systat Software, San Jose,
CA) and a one-way ANOVA was used to evaluate overall significance. The results are
presented as mean ± SEM. The confidence limit of p < 0.05 was considered statistically
significant.
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4.

Results
Generation of LXRα mutants: To identify putative residues at the LXRα interface that

may mediate interactions with PPARα, site specific mutants of LXRα were generated
based on solvent accessibility of residues located in helices 9 and 10. These helices form
the LXRα interface in the three dimensional structure of LXRα-RXRβ crystal structure
[PDB 1UHL] (26). As shown in Fig. 21A, amino acid residues H383, E387, H390, L414,
and R415 are located on the surface of helices 9 and 10 and undergo changes in solvent
accessibility upon dimerization (Table 4). These residues were predicted to stabilize the
LXRα interface. With the intent of neutralizing charge at the interface to generate LXRα
mutants that may have altered receptor selectivity, H to E, E to Q, and L to R, LXRα
mutants were generated. The assignment of helices H9 and H10 together with the point
mutations of amino acids implicated in receptor dimerization are shown in Fig. 21B.
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Fig.21. Interface of LXRα-RXRβ heterodimer showing the positioning of solvent
accessible residues (A) Contacts across the LXRα dimer interface. Location of amino
acid residues H383, E387, H390, L414, and R415 in helices 9 and 10 across the LXRαRXRβ heterodimer as proposed in the crystallographic structure (PDB 1UHL) (B)
Schematic representation of the LXRα domain structure showing single point mutations.
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TABLE 4: Exposure of Amino Acid Residues Predicted at LXRα Interface. Prediction
generated using InterProSurf Protein-Protein Interaction Server

Amino
Acid
Residue

Residue
Number

Monomer
Area (Ao)

Complex
Area
(Ao)

Change in
Accessible
Surface Area

H

383

106.38

66.79

39.59

E

387

79.59

15.15

64.44

H

390

82.98

39.46

43.52

R

415

92.80

17.52

75.28
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Full-length mutant LXRα protein purification: Recombinant full-length mutant
hLXRα proteins were expressed in Rosetta 2 cells and purified using affinity
chromatography as described for wild-type LXRα protein (44). SDS-PAGE and
Coomassie blue staining indicated predominant bands of 50 kDa corresponding to the
expected size of full-length hLXRα, for which the purity was determined to be
approximately 75% (Fig. 22). The single point mutations of LXRα did not dramatically
alter the secondary structure as was evident using far-UV CD spectrometry (data not
shown).
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Fig.22. SDS-PAGE and Coomassie blue staining of purified recombinant hLXRα
mutant proteins (A) H383E, (B) E387Q, (C) H390E, (D) L414R, and (E) R415A. The
prominent bands at approximately 50kDa are full-length, untagged recombinant mutant
LXRα proteins.
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Ligand Binding Profile of LXRα mutants: The effect of each LXRα mutation on
ligand binding was investigated. Apparent dissociation constant (Kd) values of purified
recombinant proteins for T-0901317 were determined using intrinsic quenching of
LXRα aromatic amino acids. As seen in Fig. 23A-B, titration of wild-type or H383E
LXRα proteins with T-0901317 yielded saturation curves with an apparent Kd = 3±1
nM. Titration of LXRα E387Q and H390E proteins with T0901317 also yielded
decrease in protein fluorescence, however, the binding curves exhibited smaller changes
than wild-type and H383E LXRα, suggesting lower affinity ligand binding (apparent Kd
= 24±7 nM and 26±6 nM respectively) (Fig. 23C-D). T0901317 did not cause
significant changes in the intrinsic fluorescence of the L414R and R415A proteins
suggesting no binding occurred (Fig. 23E-F). All mutants, except H390E, bound the
endogenous ligand 25-HC at nanomolar concentrations similar to that for wild-type
LXRα suggesting that mutations did not have detrimental effects on LXRα binding to
the relatively weaker endogenous ligand 25-HC (Fig. S5). None of the mutations
compromised the folding of the protein as determined by the circular dichroic spectra of
the individual proteins (data not shown). The selectivity in ligand binding was further
investigated through computational-based molecular modeling of T-0901317 to energyminimized wild-type, L414R, and R415A LXRα LBDs in the absence of water
molecules (Fig. 23G). The deviation from the positioning of ligand in wild-type was
greater in the R415A mutant than in the L414R LXRα mutant. Calculation of the
corresponding hydrogen bonds and hydrophobic interactions between the ligand and
residues lining the LXRα LBP was performed using LIGPLOT analysis. The head group
of T-0901317 formed hydrogen bonds with His421 in wild-type, H383E, E387Q, and
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H390E, but not with L414R and R415A LXRα (Fig. S6).
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Fig.23. Intrinsic quenching (A) wild-type, (B) H383E, (C) E387Q, (D) H390E, (E)
L414R, and (F) R415A LXRα aromatic amino acids by binding to T-0901317. Three
independent experiments were performed for each analysis. (G) Docking of T-0901317
to the LXRα LBD shows the relative positioning of ligand in the ligand binding pocket
of the receptor. LXRα LBD was extracted from the crystal structure of LXRα-RXRβ
(PDB entry 1UHL).
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Computational–based prediction of free energies of ligand binding in LXRα mutants:
In silico molecular docking allows distinction of binding molecules from nonbinding
molecules and is a method of choice for identification of potential binding sites for
ligand-receptor complexes. Docking was employed to evaluate and compare ligand
binding free energies of LXRα protein upon introducing mutations at the interface
(Table 5). The binding free energies of T-0901317 binding obtained from docking were
compared with the experimentally determined binding affinities of T-0901317 binding
to LXRα (Figure 23). As seen in Table 5, LXRα mutants exhibited less favorable
binding free energies for T-0901317 binding compared to wild-type LXRα. As the
apparent Kd values for ligand binding increased in the mutants, the binding free energies
also increased suggesting a decrease in affinity of T-0901317 for the mutants. One
exception was LXR H383E that bound T-0901317 with a similar affinity as wild-type,
but yielded a less favorable binding free energy from the docking simulation. It is
important to consider here that the ranking assigned by the docking simulation is not an
indication of binding constants, since the proposed models and free binding energies are
an approximation made for protein in the absence of water. Hence, caution must be
observed when comparing the predicted binding energies to the experimentally
determined dissociation constant values.
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TABLE 5: The binding free energies of T-0901317 binding to LXRα. The binding free
energies (Kcal.mol-1) of the protein-ligand complex were estimated by SYBYL

Protein

T-0901317

LXRα wild-type

-2047

LXRα H383E

-1421

LXRα E387Q

-1332

LXRα H390E

-1709

LXRα L414R

-1891

LXRα R415A

-1231
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Dimerization of LXRα mutants with PPARα: Fluorescence spectroscopy was used to
determine how efficiently each mutated form of LXRα dimerized with PPARα. Purified
PPARα protein was fluorescently labeled with Cy3 dye at essentially one dye per protein
molecule. Protein-protein binding curves were generated by plotting quenching of Cy3
dye as a function of LXRα concentration as previously described (44). The apparent
binding dissociation constant values (Kd) of each LXRα mutant- PPARα dimer were
determined. In the absence of added ligand, the apparent Kd values determined for
PPARα binding to the wild-type LXRα and each of the mutants were found to range
between 7 and 20 nM concentrations (Table 6). As seen in Fig. 24A, titration of Cy3labeled PPARα with increasing concentrations of wild-type LXRα resulted in saturable
binding curve at a low protein concentration indicative of high affinity binding. Single
amino acid substitutions H383E and E387Q also generated binding curves, with
affinities that were comparable to wild-type (Fig. 24B-C). Titration of Cy3-PPARα with
H390E, L414R, and R415A exhibited weaker quenching of Cy3 fluorescence and weak
binding was detected compared to wild-type LXRα (Fig. 24D-F). Estimation of the
apparent dissociation constants of PPARα binding to LXRα mutants showed Kd values
to be H383E < E387Q < L414R < Wild-type <R415A < H390E (Table 6). Although Kd
values for wild-type or mutant LXRα binding to PPARα were not statistically different,
differences were observed in the magnitude of Cy3 quenching by these proteins. H390E,
L414R, and R415A were less efficient in quenching Cy3-PPARα compared to other
proteins suggesting that the mutants might differentially dimerize with PPARα.
Furthermore, L414R showed weaker binding to RXRα (Fig. S7) suggesting that residue
L414 may be critical for protein-protein interactions of LXRα.
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To determine the potency of ligands to affect protein-protein interactions, the binding
affinities of PPARα for each LXRα mutant were determined in the presence of ligands
as described (44). The Kd values of each complex upon ligand binding are summarized
in Table 6. The binding of T0901317 decreased LXRα-PPARα interactions in wild-type,
H383E, E387Q, L414R, and R415A mutants. H390E LXRα bound PPARα with threefold lower affinity compared to wild-type. The addition of LXRα natural ligand, 25HC,
decreased binding of PPARα to wild-type, E387Q, and R415A LXRα and enhanced
binding to H390E and L414R mutants. The addition of PPARα agonist, palmitic acid
decreased the interaction of PPARα with wild-type, E387Q, and R415A LXRα, and
enhanced binding of H390E and L414R to PPARα (Table 6). These observations
suggest that complexes composed of PPARα and LXRα mutants respond differentially
to the addition of ligands.
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Fig. 24. Effects of mutations on dimerization of LXRα with PPARα. Cy3-labeled
PPARα was titrated against increasing concentrations of unlabeled LXRα in the absence
of ligand. Representative curves from fluorescence binding experiments are shown for
binding of each LXRα mutant to PPARα. At least three independent experiments were
performed for each analysis. Kd values represent means ± the standard error.

127

TABLE 6: Binding affinities of LXRα mutants for PPARα in the absence or presence of
ligands (T-0901317 and 25-HC for LXRα and C16:0 FA for PPARα)

Protein
No ligand
T-0901317
25-HC
C16:0 FA

Wild-type
Kd (nM)
7±3
35 ± 6
16 ±3
104 ±40

H383E
Kd (nM)
1.1 ± 0.2
8± 2
1 ± 0.2
5± 0.5

E387Q
Kd (nM)
4±1
43 ± 7
40 ± 9
21± 9
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H390E
Kd (nM)
20 ± 9
3±1
2±1
3±1

L414R
Kd (nM)
6±2
28 ± 6
2 ± 0.9
3± 0.6

R415A
Kd (nM)
8±2
18 ± 13
56 ± 12
31 ± 17

Conformational changes in dimers composed of LXRα mutants and PPARα: Nuclear
receptors are known to undergo conformational changes in the secondary structure upon
binding to ligands or other macromolecules. Previous work demonstrated that PPARα
and LXRα undergo a change in conformation upon interaction (44). The CD spectra of
mutant LXRα proteins alone were qualitatively similar to that of wild-type suggesting
that mutations do not impact the overall secondary structure of the mutant proteins (data
not shown). To examine protein-protein interactions between PPARα and LXRα
mutants, CD spectrum were measured upon mixing of proteins (Obs.) that was
compared to the average of the sum of the ellipticities of the unmixed proteins (Calc.).
As seen in Fig. 25A-D, spectra of mixtures of each mutant LXRα H383E, E387Q, and
H390E with PPARα exhibited a more negative ellipticity at 222 and 208 nm similar to
the spectra observed with wild-type LXRα-PPARα mixture. This suggests that binding
of wild-type LXRα, and LXR H383E, E387Q, and H390E with PPARα resulted in a
slight increase in the overall α-helical content. The observed spectra of LXRα L414R
and R415A, in the presence of PPARα, either overlaid the calculated spectra or showed
insignificant changes at the wavelengths of 222 and 208 nm (Fig. 25E-F). This suggests
that PPARα binds weakly with L414R and R415A or protein binding is not
accompanied by conformational changes in the overall secondary structures.
Quantitative analyses confirmed these data, with no significant changes observed with
L414R and R415A binding to PPARα (Table 7). Since, the mutants retained binding to
either T-0901317 or 25-HC, the effect of ligands on the secondary structure of the
dimers composed of PPARα and each of the LXRα mutants was investigated. None of
the ligands tested caused significant ligand induced structural changes in dimers
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composed of PPARα and L414R or R415A (Fig. S8). This suggests that ligands cause
structural changes in the individual proteins, but not in the dimer composed of PPARα
and LXRα L414R or R415A.
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Fig. 25. Far UV CD of the mixture of PPARα and LXRα proteins. Experimentally
observed (Obs, open circles) circular dichroic spectrum of a mixture of 0.2 µM PPARα
and 0.2 µM (A) wild-type, (B) H383E, (C) E387Q, (D) H390E, (E) L414R, and ((F)
R415A LXRα compared to the calculated average (Calc, closed circles) of the
individually obtained PPARα and LXRα spectra representing non-interacting proteins.
The amino acid molarity for each spectrum was 0.0002 M, and each spectrum represents
the average of at least three replicates, scanned 5 times per replicate.
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TABLE 7: Secondary structures of hLXRα and hPPARα proteins in the absence of
ligandsa

Proteins
LXRα
PPARα
PPARα/LXRα
(Obs)
PPARα/LXRα
(Calc)
PPARα/LXRα
H383E (Obs)
PPARα/LXRα
H383E (Calc)
PPARα/LXRα
E387Q (Obs)
PPARα/LXRα
E387Q (Calc)
PPARα/LXRα
H390E (Obs)
PPARα/LXRα
H390E (Calc)
PPARα/LXRα
L414R (Obs)
PPARα/LXRα
L414R (Calc)
PPARα/LXRα
R415A (Obs)
PPARα/LXRα
R415A(Calc.)

α-helix
regular
H(r)%
29.7 ± 1.0
28.0 ± 0.0
32.3 ± 1.2b

α-helix
distort
H(d)%
23.3 ± 0.8
19.0 ± 1.0
25.7 ± 0.6b

β-sheet
regular
S(r)%
10.0 ± 1.0
9.3 ± 1.0
8.3 ± 0.6

β-sheet
distort
S(d)%
11.0 ± 1.0
8.0 ± 1.0
8.0 ± 1.0

Turns
T%

Unordered
U%

14.3 ± 2.0
14.3 ± 0.6
12.3 ± 0.3

11.0 ± 2.0
20.3 ± 2.0
13.0 ± 2.0

27.0 ± 0

22.0 ± 1.0

8.0 ± 0.0

10.0 ± 0.0

15.0 ± 1.0

17.5 ± 1.5

24.0 ± 2.0

16.0 ± 1.0

10.5 ± 0.5b

8.0 ± 0.0

17.5 ± 1.5

24.5 ± 0.5b

21.5 ± 1.5

17.5 ± 1.5

14.0 ± 0.5

10.5 ± 3.5

17.0 ± 2.0

19.5 ± 0.6

28.0 ± 0.0b

22.3 ± 0.6

8.6 ± 0.3

8.0 ± 1.0b

13.7 ± 0.3

19.9 ± 1.5b

23.5 ± 0.5

23.5 ± 0.5

9.5 ± 1.5

14.0 ± 0.0

15.0 ± 1.0

13.5 ± 0.5

31.5 ± 0.5b

17.0 ± 1.0

10.0 ± 0.0

9.0 ± 1.0

12.0 ± 2.0

20.5 ± 0.5b

25.5 ± 0.9

15.8 ± 0.8

9.5 ± 1.1

8.7 ± 0.7

14.5 ± 0.6

25.2 ± 0.5

26.7 ± 0.8

19.3 ± 0.8

7.6 ± 0.3b

6.6 ± 0.3

16.0 ± 0.5

23.3 ± 0.8b

27.5 ± 0.5

18.0 ± 0.0

5.5 ± 0.5

6.0 ± 0.0

16.5 ± 0.5

26.0 ± 0.0

29.2 ± 0.8

23.4 ± 0.8

10.8 ± 0.5b

8.0 ± 0.6

12.8 ± 0.9

16.4 ± 1.3

30.5 ± 0.5

23.5 ± 1.5

7.0 ± 1.0

8.5 ± 3.5

13.0 ± 2.0

16.5 ± 4.5

a

Definitions: Obs, obtained experimentally; calc, calculated average. Significant difference
between observed and calc for each protein mixture (n = 4-6). bp < 0.05.
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Analysis of dimers in living cells using Bimolecular Fluorescence Complementation
(BiFC): The ability of LXRα mutants to form heterodimers with RXRα and PPARα in
living cells using fluorescence complementation was determined. BiFC plasmids
encoding ECFP-LXRα, Cerulean-RXRα, and Venus-PPARα were generated for
transfection in mammalian cells. The cells were transiently co-transfected with BiFC
plasmids and dimerization was evaluated by fluorescence microscopy. As seen in Fig. 26,
ECFP LXRα-Cerulean RXRα and ECFP LXRα-Venus PPARα complexes yielded CFP
and YFP fluorescent signals respectively in a substantial fraction of cells suggesting that
the BiFC system has the sensitivity to detect LXRα-RXRα and LXRα-PPARα
interactions.
A similar approach was used to investigate the effect of LXRα interface mutations on
dimerization. As seen in Fig. 26, complexes of LXRα mutants H383E, E387Q, H390E,
and R415A with PPARα or RXRα showed nuclear localization and were
indistinguishable from wild-type complexes. Co-transfection of mutant L414R with
RXRα and PPARα resulted in a robust YFP fluorescence but non-existent levels of CFP
fluorescence suggesting that LXR L414R specifically inhibited LXRα interaction with
RXRα but not with PPARα. Immunoblot analysis revealed lower expression of RXRα
protein levels in samples co-transfected with L414R mutant compared to wild-type and
other mutated LXRα mutants (Fig. S9). This suggests that partner receptor that is unable
to dimerize with LXRα or binds poorly to PPARα is unstable and undergoes proteolytic
degradation.
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Fig.26. Visualization of protein complexes composed of PPARα and (A) wild-type, (B)
H383E, (C) E387Q, (D) H390E, (E) L414R, and (F) R415A LXRα in living cells using
Bimolecular Fluorescence Complementation (BiFC) analysis. Fluorescence images of
COS-7 cells expressing ECFP-LXR, Venus-PPAR, and Cerulean-RXR proteins were
acquired 24 hours after transfection with indicated plasmids.
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Residues at the LXRα interface are required for ligand-dependent transactivation
activity: The SREBP-1c promoter contains two LXREs and is activated by LXR
overexpression presumable through dimerization with endogenous RXR (108). No
information exists on the identity of genes regulated by LXRα-PPARα heterodimers.
However, unpublished data from our laboratory have identified human ApoA1 promoter
to contain putative nucleotide sequences that preferentially binds LXRα-PPARα
heterodimer. The effects of mutations on the ability of LXRα to dimerize efficiently and
hence transactivate a known promoter (SREBP-1c) and a novel promoter (ApoA1) were
evaluated using a luciferase reporter assay.

Figure 27 illustrates the effects of

overexpression of wild-type or mutant LXRα in COS7 cells in the absence or presence
of 25HC on SREBP-1c promoter activity. Since COS7 cells express low levels of
endogenous LXRα and PPARα proteins, interference of endogenous protein with the
analysis of expressed proteins was unlikely. As shown in Fig. 27, wild-type LXRα
activation of SREBP-1c promoter was slightly enhanced with the addition of 25-HC.
Overexpression of mutants H383E, E387Q, and H390E exhibited an increase in basal
promoter activity, whereas R415A exhibited similar basal activity, and L414R exhibited
lower basal activity compared to wild-type LXRα. The basal activities of LXR H383E,
E387Q, and H390E were higher than the levels displayed by wild-type LXRα in the
presence of 25-HC. This suggests that these mutations resulted in a functional change
that was independent of ligand binding for interacting with the SREBP-1c promoter.
LXRα activation of the SREBP-1c promoter in transfected COS7 cells was
suppressed by cotransfection of PPARα (data not shown) consistent with the findings of
Yoshikawa et al (108). Mutants H383E, E387Q, and H390E exhibited a ligand-induced
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repression of the promoter activity, whereas, L414R and R415A showed no change in
promoter activity with the addition of ligand. The effects on ligand-dependent activation
of the promoter were not due to effects on ligand binding as all the mutants bind 25-HC
as determined through intrinsic quenching assay (Fig. S6). Collectively, these data
demonstrate a reduced ability of LXRα mutants to transactivate SREBP-1c promoter in
a ligand dependent manner.
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Fig.27. Effect of LXRα interface mutations on luciferase reporter activation of human
SREBP-1c promoter. COS-7 cells were co-transfected with pSG5 empty vector or each
indicated LXRα plasmid and transactivation of the SREBP-1c LXRE-luciferase reporter
construct in the presence of vehicle (solid bars) and 25-HC (Gray bars) was measured.
Luciferase reporter activity was measured 18 hrs after the addition of vehicle or ligand
and normalized using Renilla as an internal control. Asterisks denote significant
differences due to single point mutations compared to wild-type LXRα for vehicle or 25HC treated cells: *p < 0.05, **p < 0.01, ***p < 0.001.
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Figure 28 shows the effect of LXRα mutations on the ability of LXRα to transactivate
ApoA-1 promoter. Overexpression of each of the mutants H383E, E387Q, and L414R
alone exhibited similar basal activity as wild-type LXRα. LXRα H390E exhibited
enhanced basal activity, whereas R415A exhibited decreased basal activity compared to
wild-type LXRα overexpression. This suggests that R415, but not L414, H383E, E3387,
and H390, is critical for basal transactivation activity of ApoA1 promoter. All LXRα
mutants tested exhibited decreased ligand-induced activation suggesting that the
presence of each of these residues is required for ligand-dependent transactivation
function of ApoA1 promoter. Cotransfection of LXRα and PPARα resulted in
suppression of ApoA1 promoter activity similar to the effects observed on SREBP-1c
promoter (data not shown).
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Fig.28. Effect of LXRα interface mutations on luciferase reporter activation of human
ApoA1 promoter. COS-7 cells were co-transfected with pSG5 empty vector or each
indicated LXRα plasmid and transactivation of the ApoA1 luciferase reporter construct
in the presence of vehicle (solid bars) and 25-HC (Gray bars) was measured. Luciferase
reporter activity was measured 18 hrs after the addition of vehicle or ligand and
normalized using Renilla as an internal control. Asterisks denote significant differences
due to the single point mutations compared to wild-type LXRα for vehicle or 25-HC
treated cells: *p < 0.05, **p < 0.01, ***p < 0.001.
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5.

Discussion:
The LBD of LXRα, similar to other nuclear receptors, is a multifunctional domain

that mediates ligand binding, heterodimerization, cofactor recruitment, and liganddependent transactivation function. The three dimensional crystal structure of LXRαRXRα LBD complex provides useful information regarding the identity of LXRα amino
acid residues essential for dimerization. As proposed in the LXRα-RXRβ crystal
structure, residues H383, E387, H390, and R415 in LXRα showed significant changes
compared with other RXR dimers (26). Sequence alignment coupled with solvent
accessibility further showed that residue L414 may also stabilize the dimer interface to
mediate LXRα heterodimerization. Dimerization was evaluated through two approaches:
(1) in vitro protein-protein binding assays, and by (2) bimolecular fluorescence
complementation system in living cells. Our results demonstrate that the carboxylterminal amino acid of hLXRα (L414) is required for the formation of LXRα-RXRα
complexes. Cell based BiFC analysis demonstrated that mutation of L414 to arginine
resulted in disruption of LXRα-RXRα interactions, but not LXRα-PPARα interactions
consistent with the in vitro findings. Complete conservation of LXRα L 414 in the
corresponding sequences of other NRs suggests that this residue stabilizes proteinprotein interactions with RXR in other heterodimeric pairs as well. Interestingly, a
previous work identified a hPPARα point mutation (L433R corresponding to L414 in
LXRα) that also abolished dimerization with RXR (109). Our findings combined with
these previous results strongly suggest that the dimerization interface contains a leucine
residue in LXRα, PPARα, and possibly other NRs that is indispensable for protein-

144

protein interactions with RXR.
Since LXRα H390E and L414R were less efficient in binding PPARα compared to
wild-type LXRα, the possibility that these changes might reflect altered receptor
conformations due to mutations themselves was considered. CD spectrum of each of the
purified mutant LXRα proteins was found to be qualitatively similar to the spectra
observed with wild-type LXRα protein suggesting that mutations alone did not result in
gross conformational changes in the secondary structure of the proteins (data not
shown). However, the calculated and the observed spectra of mixture of PPARα with
either L414R or R415A were indistinguishable suggesting no observable conformational
changes occurred in the proteins due to protein-protein binding. Subtle differences were
observed between the calculated and the observed CD spectra for H383E, E387Q, and
H390E LXRα in the presence of PPARα suggesting that binding of these proteins is
accompanied by conformational changes in the dimer structure. It can be concluded that
PPARα binding to LXRα H383E, E387Q, H390E, but not L414R and R415A, resulted
in conformational changes in the secondary structure of the dimers.
Introduction of mutations L414R and R415A abolished binding of LXRα to synthetic
agonist T-0901317, but not to 25-HC. A previous study with R415A mutant
demonstrated that mutation at this position abolishes ligand dependent transactivation of
ADH promoter in response to T-0901317 addition (45). The present results support
previous conclusions that R415A is unable to respond to LXR ligand in a cell based
reporter assay. Although the purification properties and the protein yield for the mutants
were similar to those observed for wild-type LXRα protein, the altered ligand binding
properties of L414R and R415A suggest that changes at the interface might cause subtle
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rearrangement in the helices lining the LXRα ligand binding pocket.
To interpret the mutagenesis data with respect to ligand binding, molecular docking
of ligands to the LXRα LBD extracted from the LXRα-RXRβ crystal structure (1UHL)
was performed. The docked models revealed differences in the positioning of T0901317 in the ligand binding pocket of the energy-minimized mutant receptors. In
agreement with the experimental results presented here, docking of T-0901317 to the
LBDs of LXR L414R and R415A was associated with unfavorable binding energies
suggesting that these residues are critical for high affinity ligand interactions. LigPlot
analysis showed that the head group of T-0901317 is positioned further away from
His421 in the ligand pocket of LXRα mutant R415A (Fig. S6). Residue His421 in the
LBP has been reported to be critical for agonist binding to LXRα (26) and differential
positioning of T-0901317 in R415A relative to wild-type LXRα could explain the
inability of this mutant to bind T-0901317.
The effect of mutations on the ability of LXRα to transactivate two promoters:
SREBP-1c and ApoA1was also examined. The data demonstrated that residues H383,
E387, and H390 are not necessary for basal activity of unliganded LXR, but are required
for ligand-dependent transactivation function. Replacement of L414 with arginine
significantly reduced SREBP-1c promoter reporter activity in a ligand dependent as well
as ligand independent fashion without affecting the nuclear localization of LXRα. This
supports the idea that conserved L414 in LXRα may be essential for ligand-independent
and ligand-dependent transactivation functions. We postulate that substitution of a nonpolar, hydrophobic amino acid, leucine, for the basic amino acid residue arginine may
disrupt an ionic interaction or change the hydrophobic nature of the LXRα interface. As
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most of the residues involved in the interactions between proteins and alpha-helices are
hydrophobic in nature (110), introducing charge may prove detrimental for the
formation of LXRα-RXRα, but not for LXRα-PPARα interactions. Moreover, the
presence of two arginine residues adjacent to each other in L414R mutation may further
contribute to destabilization of the dimer.
We next investigated whether the effect of L414R mutation on transactivation is
promoter specific. The basal transactivation activity of L414R was indeed similar to that
of wild-type LXRα on the ApoA1 promoter. However, the ligand dependent
transactivation activity on the promoter was abolished. These findings suggest that the
LXRα mutants have differential effects dependent upon promoter context. Thus, a
mutant that is non responsive to the addition of ligands and unable to regulate a specific
gene may be activated by different agonists and could regulate different subset of genes.
The findings here have important implications for the development of novel therapies, in
particular for the design of LXR modulators in the treatment of metabolic disorders. For
example, it would be desirable to design a molecule that mimics the effects of L414R
mutation

such

that

it

exhibits

modest

SREBP-1c

activity

(to

prevent

hypertriglyceridemia) whilst up-regulating transcription of beneficial genes such as
ApoA1 (to enhance reverse cholesterol transport).
In conclusion, this study provides insights into the functional roles of LXRα helices 9
and 10 and the long-range effects mutations may have in modulating various functions
of LXRα. Evidence was provided that maintenance of hydrophobic interaction mediated
by L414 at LXRα interface is required for dimerization with RXR and for optimal
ligand-dependent transactivation function of LXRα. The data suggests that LXRα
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mutants (identified here and other mutants implicated in metabolic disorders) may
behave differently depending upon the nature of: (a) mutation, (b) ligand tested, and (c)
the promoter under consideration. Moreover, the fact that the conserved leucine is also
required for dimerization and transactivation of PPARα (and possibly other NRs)
suggests the existence of a common mechanism for ligand-dependent transactivation
among lipid sensing nuclear receptors.
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SUMMARY AND CONCLUSIONS
Cholesterol plays several structural and metabolic roles that are vital for human
biology. However, excess cholesterol can lead to pathological conditions such as
atherosclerosis, which is a consequence of the accumulation of cholesterol into the cells
of the arterial wall. As cholesterol is both crucial and lethal, organisms have developed
regulatory networks to ensure maintenance of lipid homeostasis. LXR functions as a
cholesterol sensor that regulates cholesterol transport and metabolism. The popularity of
LXRs as attractive pharmacological targets stems from the fact that, in addition to
playing a key role in maintaining cholesterol homeostasis, these receptors contain a
hydrophobic pocket that binds a variety of small hydrophobic molecules (111, 112).
Various synthetic LXR ligands that display anti-atherogenic properties in mice have
been developed. Despite the favorable responses induced by LXR agonists in animal
models, these compounds have not progressed to human trials due to side effects such as
hypertriglyceridemia. Hence, there has been an immense interest in identifying novel
ligands for LXRs, synthetic as well as natural, that may be tweaked to design better
drugs with fewer adverse effects in the treatment of metabolic disorders.
The identification of ligands may be performed based on function, such as
transactivation of a reporter gene in a transient transfection assay or via direct binding to
the receptor. Herein, we have utilized both strategies to investigate the effects of chain
length and degree of unsaturation on fatty acid binding to LXRα. We have reported
interactions between full-length LXRα protein and fatty acids in quantitative terms
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(dissociation constant values) and demonstrated that transactivation activity of LXRα is
modulated in response to 25-HC (canonical endogenous ligand) and medium chain fatty
acids (novel ligand). Although transactivation assays are a method of choice for
identifying novel ligands and/or potential drugs, these assays may lead to false positives
by identifying receptor activators, of which only a subclass may actually be bona fide
ligands. The compounds could, for example, alter a signal transduction pathway that in
turn affects the phosphorylation state of the receptor, and it is that phosphostate, and not
direct ligand binding, that affects function. It is also possible in reporter gene assays that
a compound may activate an endogenous receptor, which in turn affects the expression
and/or activity of the ectopically expressed receptor being tested (113). Alternatively, a
compound could be a precursor to the true ligand, as may be the case for the free fatty
acids that were originally identified as ligands for PPARα by transfection assays (114).
To circumvent these problems, we utilized a variety of biophysical assays to provide
evidence of direct binding of fatty acids to LXRα. Our data strongly suggests that
medium chain fatty acids and/or their acyl CoA derivatives bind LXRα with high
affinities (low nanomolar concentrations) and that such binding may or may not involve
drastic changes in the secondary structure of the protein. Interestingly, there is a
structural similarity between oxysterols and 25-dihydroxy-vitamin D3 suggesting that
this metabolite could also potentially act as an LXRα agonist. The relative binding
affinities and the functional significance of vitamin D binding to LXRα will be worth
investigating in future.
The finding that dietary fatty acids can bind to LXRα and exhibit enhanced activity
on SREBP-1c promoter suggests that these lipids are not just energy sources but
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regulators of LXRα target genes. But the obvious question that arose was whether
medium chain fatty acids have the potential to reach high enough concentrations in cells
to activate LXRs. Although MCFA constitute a very minor fraction of the free fatty
acids in plasma, these FA can be greatly elevated in certain disease states (115). Under
these conditions, MCFA are likely to be present intracellularly at concentrations that are
in good agreement with their dissociation constant (Kd) values. Thus, MCFA binding to
LXRα is biologically relevant.
The activity of LXR is not only modulated through ligand binding, but also through
posttranslational modifications such as glycosylation, ubiquitination, acetylation,
sumoylation, and phosphorylation (51-54). One of the major concerns with the use of
bacterially purified proteins in enzymatic assays is that the preparation might not be
identical to the naturally occurring wild-type protein. The lack of efficient
posttranslational modifications in bacterial cells might result in the purification of
protein that might be largely insoluble or is improperly folded (116). Although we did
not encounter such issues in the purification of recombinant LXRα, the possibility
remains that lack of posttranslational modifications may have profound effects on
responses to nutritional cues, receptor stability, or interactions with other nuclear
proteins such as coactivators/corepressors etc. However, findings of our mammalian cell
based transactivation assays were found to be in close agreement with the in vitro data
obtained with bacterially purified proteins. This suggests that the in vitro results were
not an artifact of the reaction conditions.
MCFA as treatment for metabolic disorders- Lifestyle-related diseases, such as
obesity, hyperlipidemia, atherosclerosis, type 2 diabetes and hypertension, are
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widespread and increasingly prevalent in industrialized countries. Subjects with
metabolic syndrome have a threefold higher risk of developing coronary heart attack or
stroke, and a twofold higher cardiovascular mortality than those without the syndrome.
MCFA, present in coconut oil, palm kernel oil, butter, milk, yogurt and cheese, have
been used for the dietary treatment of malabsorption syndrome because of their
metabolic properties (117). Additionally, several reports suggest that MCFAs/MCTs
offer the therapeutic advantage of preserving insulin sensitivity in animal models and
patients with type 2 diabetes and cardiac diseases (118). Whether MCFAs/MCTs
regulate these processes through modulation of LXRα will be of great interest in future
studies. Since MCFA have also been shown to bind and modulate PPARγ, the
therapeutic potential of MCFAs/MCTs in treating metabolic syndrome may be a
combinatorial effect mediated through both receptors. Despite promiscuity displayed by
nuclear receptors with respect to ligand binding, our data strongly suggests that MCFA
are natural physiologically relevant LXRα modulators.
A recent study revealed three critical mutations in the LXRα LBD comprising of
amino acids E324, P327, and R328. This mutation is responsible for the inability of
LXRα LBD to interact with its endogenous ligands leading to deregulation of target
genes (119). As the classical endogenous LXRα ligands mostly comprise of four linked
hydrocarbon rings, it is possible that the distorted LBD in the triple mutant receptor is
unable to accommodate the bulky steroid structure of oxysterols. On the other hand,
MCFA that lack the bulky ring structures are more likely to fit in the LXRα triple
mutant LBD. Future studies might explore MCFA as an alternative therapeutic option
that may be used for treating such patients.
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Ligand regulated dimerization of LXRα and PPARα- One of the debated questions is
whether dimerization between LXRα and PPARα is induced by ligand binding. Several
previous studies have utilized truncated forms of proteins to measure the binding
affinities of LXRα mediated complexes (43). In contrast, this study focused on the
interactions of full-length proteins (LXRα and PPARα) to demonstrate that binding
dissociation constants of full-length proteins are different from those of LBDs.
Unliganded LXRα protein bound PPARα at low nanomolar concentrations (Kd value of
8±2nM) indicative of high affinity binding. Furthermore, presence of ligands modulated
the Kd, values for dimerization possibly through amino acid side-chain rearrangements.
Although we have previously reported that the high affinity interaction between PPARα
and LXRα proteins is abolished by the addition of polyunsaturated fatty acids and
enhanced by the addition of relatively shorter saturated fatty acids (44), the effect of
LXRα ligands on these interactions had not been investigated. This study allowed us to
determine quantitatively the effects of LXRα ligands on LXRα-PPARα heterodimer. All
ligands tested induced distinct conformational changes that either promoted or
destabilized the formation of heterodimers. Interestingly, the control of dimerization by
LXRα ligands did not always correlate with the binding affinities of these compounds
for the receptor highlighting the complexity of regulation of dimerization of LXRαPPARα by ligand binding. Although I did not test the effect of pre-formed LXRαPPARα dimers on ligand binding, the expectation is that dimerization is likely to
influence ligand binding due to allosteric effects propagated from the receptor interface
to the ligand binding pocket.
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It is worthwhile to mention here that our assays suggest a combination of both
ligand-mediated association of monomers into dimers as well as ligand-mediated
changes in the conformation of dimers. Whether treatment with ligand modulates the
level of LXRα homodimers has not been addressed in the study. Enhancement of
homodimerization has been reported for a few GPCRs in which agonist treatment leads
to a decrease in the level of dimers, with a corresponding increase in the level of
monomers (120). Unpublished data from our laboratory suggests that LXRα has a higher
affinity for partner receptors compared to LXRα monomers. Although the effect of
ligand

on

homodimers

was

not

investigated,

we

anticipate

that

receptor

homodimerization is likely to be modulated through ligand binding.
Given that LXRα homodimeric and heterodimeric complexes may exhibit unique
functional characteristics, the presence of ligands could selectively target homodimeric
species in favor of heterodimeric complexes or vice versa. Regardless of the effect of
ligands on homodimers or heterodimers or both, this study provides evidence that ligand
binding leads to both qualitative and quantitative changes in heterodimerization that
might have significant therapeutic implications.
LXRα L414 may be critical for LXRα-RXRα but not LXRα-PPARα interactions: The
role of the LXRα-LBD interface in the functioning of the full-size receptor was verified
through functional analysis of carefully selected mutations of residues exposed on the
contact surface. I demonstrated that mutations can be computationally predicted and
could be applied to design LXRα variants that show selective binding. Using the known
crystal structure of LXRα LBD, I generated five LXRα single point mutants for
experimental testing. LXRα interactions with both RXRα and PPARα were considered.
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Ligand binding and mutations at the LXRα interface modulated protein-protein
interactions of LXRα with partner receptors. I identified mutations at the LXRα interface
that exhibited altered apparent dissociation constant values with respect to binding
PPARα and synthetic LXRα ligand T-0901317. Replacements were predicted to either
disrupt or enhance dimerization without major impact on the secondary structure of
LXRα and without altering other important functions. In fact, we detected minor
changes in ligand-binding properties for LXRα variants with respect to binding 25-HC.
All substitutions tested had dramatic consequences on the transactivation activities.
Interestingly, all LXRα variants showed higher basal transactivation activity than the
wild-type receptor. How interface mutants exhibited enhanced basal transactivation
remains unclear. L414R nearly completely disrupted activity when tested with SREBP1c promoter but retained wild-type like activity with ApoA1 promoter. On the other
hand, R415A exhibited strongly reduced transactivation activity with ApoA1 promoter.
Our results are consistent with published data on LXRα R415A that has previously been
reported to affect transactivation (ADH promoter) and/or ligand binding (T-0901317)
(45). Our data now points out that the detrimental effects of R415A on transactivation
are not due to disruption in LXRα dimerization, but probably due to defective DNA
binding or cofactor recruitment. Altogether, the current findings demonstrate that LXRα
LBD dimerization surface is critical for the transcriptional activity of the LXRα.
Furthermore, dimer contacts at the LXRα interface may provide a link between ligand
binding and dimerization and the relationship between ligand binding and dimerization
in LXRα is probably more complex than previously thought.
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To date, a few mutations in the LXR-LBD have either been linked to human diseases
or demonstrated to disrupt ligand binding or transactivation properties. Previously
available structures of monomeric LXR-LBD allowed for a straightforward
rationalization of the impact of mutations that directly affect hormone binding or
protein-protein interactions. Mutations in residues that line AF-2 explain further the
basis for ligand dependent transactivation activity. The current LXRα-RXRβ structure
suggests an elegant map of allosteric connections between major LXRα functional sites
with important implications for signal transmission across the LBD. We provide
structure-function insights into how mutations of key residues that cluster at the dimer
interface alter key functions of the LXRα. Even though caution must be exercised when
extrapolating the current results to other NRs, strong conservation of residues at
corresponding positions in other nutrient sensing receptors argues in favor of similar
roles in other NRs as well. Despite the inherent challenges in developing protein–protein
modulators, our findings suggest that small molecules that may modulate LXRα
dimerization could be potentially useful in the treatment of cardiovascular diseases.
Phenocopy- The identification of LXRs as regulators of cholesterol makes them
important drug targets to stimulate cholesterol efflux from lipid-laden macrophages (18).
Presently, several pharmaceutical companies are working to develop agonists that
exhibit beneficial effects without the detrimental stimulation of triglyceride synthesis
inherent to existing LXRα agonists. This study identified L414R variant as having
selective dimerization properties. The observation that L414R selectively binds PPARα,
and not RXRα, and responds to the endogenous ligand 25-HC, and not T0901317, has
potential implications in drug discovery and development. Moreover, this mutant has
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lower transactivation activity when challenged with ligand on SREBP-1c promoter but
retains normal wild-type like activity on ApoA1 promoter. Since ApoA1 is the protein
component of high density lipoproteins and mediates efflux of cholesterol from the
macrophages, L414R presents a possible solution for dissociating the favorable effects
of LXRα stimulation from their unwanted effects. The phenocopy phenomenon has been
used for drug discovery processes through inhibiting a drug target with different
functional modulation technologies and thereby mimicking a phenotype of interest
(121). The term phenocopy was introduced by Goldschmidt to describe environmentally
induced developmental defects which resemble mutant phenotypes (122). Inhibition can
be achieved using RNA interference (RNAi), to knockdown a target, or by small
molecule inhibitors to block or inhibit the activity of the target. Final proof that
phenocopy of L414R may offer a solution to the triglyceride-raising problems of the
LXR stimulation must await the identification of molecules that will mimic L414R
effects in the receptor. However, evidence presented herein makes a compelling case for
attempting to identify such molecules to develop strategies in combating metabolic
disorders.
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APPENDIX

Supp. Table 1. Affinity of hLXRα for non-fluorescent ligands determined by quenching
of hLXRα aromatic amino acid fluorescence (Kd) and ligand efficiencies determined by
displacement of hLXRα-bound BODIPY C16-CoA (Ki).

Ligand

Chain length:
double bonds
(position)
Palmitoleic acid
C16:1 (n-7)
Palmitoleoyl-CoA
C16:1 (n-7)
Stearic acid
C18:0
Stearoyl-CoA
C18:0
Oleic acid
C18:1 (n-9)
Oleoyl-CoA
C18:1 (n-9)
Linoleic acid
C18:2(n-6)
C18:2(n-6)
Linoleoyl-CoA
C20:4 (n-6)
Arachidonic acid
Arachidonoyl-CoA
C20:4 (n-6)
Docosahexanoic acid
C22:6
Docosahexaenoyl-CoA C22:6
22 (R) Hydoxycholesterol
25-Hydroxycholesterol

Kd (nM)

Ki (nM)

102±58

N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
N.D.
1.2±0.3
N.D.

34±12
16±5
>197
45±15
>68
16±4
>61
27±8
16±7
>80
19±4
N.D.
17±4

Values represent the mean ± S.E. (n ≥ 3). ND, not determined.
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Supp. Table 2. Secondary structures of hLXRα protein in the presence of fatty acids
and fatty acyl-CoAs

Ligand

Ethanol
C16:1
C16:1-CoA
C18:0
C18:0-CoA
C18:1
C18:1-CoA
C18:2
C18:2-CoA
C20:4
C20:4-CoA
C20:5
C22:5
C22:6
KH2PO4
C20:5-CoA
C22:5-CoA
C22:6-CoA

α-helix
regular
H(r)%
13.9 ± 0.4
14.0 ± 1.0
14.3 ± 0.6
16.4 ± 3.2
10.3 ± 1.3
14.0 ± 1
14.0 ± 0.2
14.1 ± 1.1
7.4 ± 0.3
13.2 ± 0.2
13.9 ± 0.6
13.1±0.1
15.7±1.9
15.6±1.1
12.3±0.1
14.2±0.7
13.4 ± 1.1
14.3 ± 0.4

α-helix
distort
H(d)%
11.9 ± 0.2
11.3 ± 0.9
11.6 ± 0.6
11.7 ± 0.8
9.7 ± 0.7
11.3 ± 0.9
10.9 ± 0.8
11.6 ± 1.2
8.5 ± 0.1
10.3 ± 0.1
12.1 ± 0.3
11.6±0.2
12.2±0.4
12.2±1
9.8±0.3
12±0.5
11.6 ± 0.5
12.4 ± 0.2

β-sheet
regular
S(r)%
13.3 ± 0.3
17.0 ± 3
13.7 ± 1.4
10.1 ± 5.1
19.0 ± 2.4
17.0 ± 3
12.0 ± 6
15.0 ± 2
28.2 ± 9.8
16.1 ± 2.9
14.21 ± 0.9
14.8±0.8*
10.1±4
14±3
16.5±1.8
14±0.1
14.9 ± 1.7
13.2 ± 0.8

β-sheet
distort
S(d)%
8.8 ± 0
10.1 ± 0.9
9.3 ± 0.3
9.2 ± 0.4
10.4 ± 0.5
10.1 ± 0.9
9.0 ± 0.1
9.4 ± 1.1
10.8 ± 0.1
10.1 ± 0.1
8.9 ± 0.2
9.1±0.1
8.3±0.6
9.5±0.8
9.7±0.3
8.8±0.4
9.2 ± 0.3
8.5 ± 0.1

Turns
T%

Unordered
U%

19.6 ± 0.8
20.9 ± 0.5*
20.6 ± 0.6
16.9 ± 3.4
20.1 ± 1.1
20.9 ± 0.5
18.9 ± 0.2
20.9 ± 1.1
25.4 ± 0.4
21.3 ± 0.5
20.9 ± 0.3
20.8±0.1
19.8±1.5
21±0.4
19.2±0.3
21.1±0.5
20.6 ± 0.6
20.6 ± 0.5

32.4 ± 1.5
26.5 ± 2.4
30.2 ± 1.1
35.4 ± 4.8
30.4 ± 2.0
26.6 ± 2.4
35.2 ± 0.6
28.9 ± 1.3
19.4 ± 9.7
28.7 ± 0.2
30.0 ± 0.5
30.5±0.7
33.8±4
27.5±1.8
32.4±0.7
29.9±0.1
30.2 ± 1.1
30.9 ± 0.9

Significant difference between hLXRα with solvent compared to the absence or
presence of fatty acids or fatty acyl-CoA dissolved in either ethanol or in KH2PO4 were
determined by t-test * = P<0.05, ** = P<0.01, *** = P<0.001.
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Fig S1: Forster resonance energy transfer (FRET). Unlabeled LXRα (donor) (excitation
wavelength 280 nm) was titrated against increasing concentrations of BODIPY C12:0 or
BODIPY C12:0-CoA (acceptor) (emission wavelength 300-540 nm). Changes in the
fluorescence intensity at 341 nm wavelength were plotted as a function of ligand
concentration to determine apparent dissociation constant (Kd) values.
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Fig. S2: Displacement assay of BODIPY C16:0-CoA bound LXRα. BODIPY C16:0CoA bound to LXRα was displaced with LXRα endogenous ligand 22 (R)
Hydroxycholesterol, but not with long chain fatty acids docosahexaenoic acid and
phytanic acid.
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Fig. S3: Direct binding assay based on quenching of LXRα aromatic amino acid
fluorescence emission when titrated with the following ligands (A) Stearic acid, (B) Oleic
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Fig. S5. Effects of LXRα interface mutations on ligand binding of (A) wild-type, (B)
H383E, (C) E387Q, (D) H390E, (E) L414R, and (F) R415A LXRα to 25-HC. All
mutants, except H390E, showed reduced binding affinity compared to the wild-type.
Three independent experiments were performed for each analysis.
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Fig. S6: Ligplot representations of hydrogen bonds and hydrophobic interactions
between T-0901317 and (A) wild-type, (B) H383E, (C) E387Q, (D) H390E, (E) L414R,
and (F) R415A LXRα. Dashed lines represent hydrogen bonds and spiked residues form
hydrophobic contacts with the ligand. Figures were generated in Ligplot+ and LigEd.
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Fig. S7. Fluorescent protein-protein binding assay of Cy3-labeled RXRα titrated against
increasing concentrations of unlabeled LXRα. The change in fluorescence intensity of
25nM Cy3-labeld RXRα was titrated with increasing concentrations (0-250 nM) of (A)
Wild-type LXRα, (B) L414R LXRα, (C) R415A LXRα.
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Fig. S8. Far UV CD of the PPARα and (A) wild-type; (B) H383E; C) E387Q; (D)
H390E; (E) L414R; or (F) R415A LXRα proteins in the absence (filled circles) and
presence of added ligands: T-0901317 (open circles) or 25-HC (filled triangle) or C16:0
FA (open triangle). The amino acid molarity for each spectrum was 0.0002 M, and each
spectrum represents the average of at least three replicates, scanned 5 times per replicate.
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Fig. S9. Detection of the expression levels of BiFC proteins by western blot analysis.
COS-7 cells were transfected with the indicated expression plasmids (700 ng). Cell
lysates were analyzed by 12% SDS-PAGE and transferred to a nitrocellulose membrane.
The expression of BiFC-PPARα and BiFC-RXRα proteins were detected by using a
rabbit anti-PPARα serum (provided by Dr. Hardwick) and rabbit anti-RXRα antibody
(SC-553, Santa Cruz).
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LIST OF ABBREVIATIONS

ABCA1

ATP- cassette transporter A1

ACC

Acetyl-CoA carboxylase

AF-1

Ligand-independent transactivation function

AF-2

Ligand-dependent transactivation function

apo-A1

apolipoprotein A-1

apoE

apolipoprotein E

BiFC

Bimolecular Fluorescence Complementation

Bodipy

Boron-dipyrromethene

CD

Circular Dichroism

CETP

Cholesteryl ester transfer protein

CYP7A

Cholesterol 7 alpha-hydroxylase

DBD

DNA binding domain

DMEM

Dulbecco’s modified Eagle’s media

DMSO

Dimethyl sulfoxide

DR 4

Direct repeat 4

ECFP

Enhanced cyan fluorescent protein

EDTA

Ethylenediaminetetraacetic acid

FA

Fatty acid

FAS

Fatty acid synthase

FBS

Fetal-bovine serum
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FRET

Forster resonance energy transfer

FXR

Farnesoid X receptor

GW3965

3-[3-[N-(2-Chloro-3-trifluoromethylbenzyl)-(2, 2diphenylethyl) amino] propyloxy] phenylacetic acid hydrochloride

HAT

Histone acetyltransferase activity

HDAC

Histone deacetylase activity

HDL

High density lipoprotein

hPPARα

Human peroxisome proliferator activated receptor α

22-R HC

22R- Hydroxycholesterol

25-HC

25-Hydroxycholesterol

IL-1

Interleukin-1

IL-6

Interlukin-6

LBD

Ligand binding domain

LBP

Ligand binding pocket

LCFA

Long chain fatty acids

LCFA-acyl CoA

Long chain fatty acyl CoA

LDL

Low density lipoprotein

LDL-C

Low-density lipoprotein cholesterol

LXRα

Liver X Receptor α

LXRβ

Liver X Receptor β

LXRE

LXR response element

MCFA

Medium chain fatty acids

MCFA-acyl CoA

Medium chain fatty acyl CoA
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NAFLD

Non-alcoholic fatty liver disease

NCoR

Nuclear receptor corepressor

NR

Nuclear receptor

PC

Photon counting spectrofluorometry

PDB

Protein Data Bank

PPRE

PPAR response element

PUFA

Polyunsaturated fatty acids

PXR

Pregnane X receptor

RAR

Retinoic acid receptor

RCSB

The Research Collaboratory for Structural Bioinformatics

RXR

Retinoid X receptor

SCD-1

Stearoyl-CoA desaturase

SDS PAGE

Sodium dodecyl sulfate polyacrylamide gel electrophoresis

SMILE

Small heterodimer partner interacting leucine zipper protein

SMRT

Silencing mediator of retinoid acid and thyroid hormone receptor

SPDBV

Swiss PDB Viewer

SRC-1

Steroid receptor coactivator

SREBP

Steroid regulatory element-binding protein

T-0901317

N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1(trifluoromethyl)ethyl]phenyl]-benzenesulfonamide

UGT

UDP-glucuronosyltransferase

VDR

Vitamin D receptor
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